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Summary 
Prostate cancer is the most common cancer in males and the second leading cause of cancer 
deaths in western countries. Although most prostate cancers initially respond well to androgen 
withdrawal, they become inevitably resistant to this treatment and progress to hormone-
insensitive disease after only a few months or years. The therapeutic options in these 
advanced tumors are very limited. The molecular mechanisms of how prostate cancers escape 
hormonal treatment are poorly understood. Identification of genetic alterations including 
amplifications could elucidate genes with oncogenic properties to be used as new therapeutic 
targets in this deadly disease. Here, we investigated amplification at 10q22 that prevails in 10-
15% of hormone-insensitive prostate cancers and in the hormone-insensitive prostate cancer 
cell line PC-3. A core region 7 Mb of the amplicon was chosen for detailed analysis. The 
amplification profile of this region was unexpectedly flat and did not allow us to narrow down 
the region of interest or select a candidate gene based its location within the amplicon.  
A number of potentially interesting genes within the amplified region based on the established 
or presumed biologic functions were tested for amplification and mRNA expression status in 
the prostate cell lines. The calcium-activated large-conductance potassium channel 
(KCNMA1) was chosen for detailed analysis as it showed the most consistent association 
between amplification and overexpression. It was highly expressed in the prostate cancer cell 
line with KCNMA1 amplification (PC-3) as compared to the non-amplified cell lines LNCaP, 
CWR22R, and BPH-1. Other interesting candidates that are amplified at 10q22 include 
PLAU, VDAC2, PSAP, CAMK2G, and PPP3CB. First, we ascertained that KCNMA1 
amplification prevailed also in vivo using fluorescence in situ hybridization (FISH) with a 
probe specific for KCNMA1. Amplification was found in 16% of 119 late-stage human 
prostate cancers but not in 33 benign controls, 32 precursor lesions and in 105 clinically 
organ-confined prostate cancers on a prostate tissue microarray.  
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Modulation of the BK channel activity in vitro revealed that BK channel promotes growth of 
prostate cancer cell lines. In more detail, specific inhibition of BK channel in PC-3 by 
iberiotoxin reduced growth of this cell line but had no significant effect on BPH-1and 
LNCaP. This effect was even much more pronounced by RNA interference as shown in PC-3. 
This growth inhibition by RNA interference was paralleled by changes of cell size and shape, 
suggesting that BK channel may be involved in the regulation of cell volume. Interestingly, 
estradiol enhanced the growth of BPH-1 and LNCaP, but did not affect the growth of PC-3. 
The effect of estradiol on LNCaP and BPH-1 was prevented by iberiotoxin. This finding 
suggests that estradiol mediates the effect of estradiol on the growth of prostate cells that do 
not overexpress BK channel.  
Taken together, our data suggest that the BK channel system is involved in the regulation of 
growth of prostate cancer cell lines and putatively also in the progression of prostate cancer in 
vivo. This makes KCNMA1 a potential therapeutic target in patients with prostate cancers 
that harbor KCNMA1 amplification. However, further studies are needed to investigate 
KCNMA1 in human prostate cancer, as we found no significant association between gene 
dosage and expression in a preliminary series of fresh-frozen specimens from hormone-
insensitive local recurrences. Similarly, the precise mechanisms by which KCNMA1 
contributes to growth regulation remain to be elucidated. 
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1. Introduction 
1.1. Epidemiology of prostate cancer 
Prostate cancer is the most frequent cancer and the second leading cause of cancer related 
death in male 1. The risk to be diagnosed with this cancer is very low in men below 50 years 
of age but greatly increases with advancing age. This strong association with age suggests 
changes in the aging male organism that favour development of prostate cancer. Importantly, 
only a small fraction of histologically detectable prostate cancers cause clinical symptoms 
during the patient’s lieftime. The lifetime risk of 8% to be diagnosed prostate cancer contrast 
with the high autopsy based prevalence of up to 80% by the age of 802-4. Thus, most men die 
with prostate cancer rather than from prostate cancer 5,6.  
Widespread PSA screening for early stage prostate cancer during the past two decades has 
lead to a dramatic increase in the number of patients diagnosed with prostate cancer 7,8. 
Potential overtreatmant of patients with PSA detected prostate cancer has become a major 
clinical concern 7,8. Epidemiology suggests a genetic predisposition for prostate cancer, 
although no classical familial prostate cancer syndrome is known 9-11. There is also a large 
racial difference in prostate cancer incidence. Afro-American men have a significantly 
increased risk for prostate cancer as compared to white (Caucasian) Americans. In turn, 
Caucasian Americans have a significantly increased risk compared to Americans of Japanese 
origin 12. This might be due to different live stile especially including dietary habits 13,14. 
Especially the consumption of high amount of fat is suggested to be a risk factor for prostate 
cancer. In contrast, regular intake of lycopenes from tomatoes is considered as a protective 
factor 15.  
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1.2. Prostate cancer development and progression 
1.2.1. Benign prostate 
Normal prostate glands are composed of three major cell types. Secretory luminal cells that 
express PSA and cytokeratins 8 and 18 16-19. Basal cells mediate attachment to the stroma and 
express high molecular weight cytokeratins. The third phenotype shows neuroendocrine 
differentiation and expresses chromogranins and neurosecretory products that may have 
growth promoting functions. Most likely, these cell types share a common origin from 
pluripotent stem cells located in the basal cell layer 18,20-23. In healthy prostate the proliferation 
compartment is located in the basal cell layer24. In addition, there is a minor pool of dividing 
cells identified in secretory luminal cells.  
Cellular diversity of the prostatic epithelium is maintained by a combination of hormonal 
control, growth factors and adhesive interaction with the underlying basal membrane. 
Secretory luminal cells are androgen dependent, and require circulating androgens for their 
maintenance and maturation. These cells express high levels of nuclear androgen receptor 18. 
The basal cell compartment is not androgen dependent but remains androgen responsive. 
Subsets of these cells express androgen receptor at high levels18. Likely, these cells are 
committed to differentiate towards secretory luminal cells under appropriate androgen 
stimulation 25,26. One model predicts that differentiation of prostatic epithelium is controlled 
by a balance of estrogen to androgen levels27. The prostate contains estrogen receptor α 
(ERα) and β (ERβ). ERβ is expressed in the majority of normal prostate epithelial cells, while 
ERα is typically expressed in the stromal cells and in a fraction of basal cells 27. The 
physiological function of these receptors is not known. Estrogen treatment leads to atrophy of 
luminal cells but induces basal cell hyperplasia by preventing basal cells from differentiation 
towards luminal cells 25,26. In contrast, prolonged androgen deprivation causes enhanced 
proliferative activity of benign luminal cells, but not of basal cells 28. Given the well known 
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proproliferative function of androgens in prostate cancer it appears paradoxical that the 
incidence of prostate cancer increases as the androgen levels gradually decrease with age. It 
has been hypothesized that an imbalance between estrogens and androgens with a relative 
increase of estrogens upon aging may promote prostate cancer development 27.  
Benign Prostatic Hyperplasia (BPH) is common in male and represents a clinically significant 
cause of bladder outflow obstruction in up to 40% of men during their life time 29. However, 
BPH is not considered a PCa precursor. BPH occurs in the transitional zone of the prostate, 
whereas most clinical PCa are located in the peripheral zone of the prostate 30.  
 
1.2.2. Prostatic intraepithelial neoplasia (PIN) 
High grade PIN (HGPIN) is considered the most likely precursor of peripheral zone prostate 
cancer based on several pieces of evidence31. In autopsy series, the increase in the prevalence 
of PIN has been shown to precede the increasing prevalence of invasive prostate cancer by 
10-15 years 16. In addition, prostates with carcinoma have a higher amount of PIN than 
prostates without carcinoma. In prostate biopsies, the presence of isolated PIN is associated 
with an increased likelyhood of invasive prostate cancer at another site within the prostate 32. 
Also, molecular profiles of PIN resemble those of prostate cancer rather than those of benign 
prostate32,33. 
 
1.2.3. Prostate cancer (PCa) 
Microscopically, most carcinomas of the prostate are classical adenocarcinomas, being made 
up of epithelial cells with variably developed glandular architecture. During carcinogenesis 
the glandular structure is gradually lost. Pathological grading of the glandular organisation is 
basis of the Gleason grading system 34. Gleason grading is a strong prognosticator in prostate 
cancer.  
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1.2.4. Routes of metastasis 
Lymphatic or hematogeneous metastases have been found in 40% of men with PCa at the 
time of autopsy. Bone is most commonly involved in metatasizing PCa (90%), followed by 
lung (46%), liver (25%), pleura (21%), and adrenals (13%) 35. Most bone metastases prevail 
in the lower  spine (90% of cases of bone metastases) while other bones such as ribs (18%), 
long bones (15%), and skull (8%) are less commonly affected. 
This metastatic pattern strongly suggests that distant spread of prostate cancer follows two 
different paths. A first metastatic pathway is a backward metastatic spread to the lower spine 
due to anastomosis between the periprostatic and the paravertebral venous plexus. A second 
pathway is a cava-type metastasis to lung, and from there to other organs35. 
 
1.3.Prostate specific antigen (PSA) 
The wide spread use of PSA screening since the late 1980 coupled with improved diagnostic 
techniques and increased disease awareness, has led to a diagnosis of prostate cancer at earlier 
stages and at a younger age than in the pre PSA area 36. The risk of prostate cancer increases 
gradually as the PSA value increases from more than 4ng/ml to higher values 37. The higher 
proportion of pathologically organ-confined cancers due to early detection increases the 
likelihood of cure, which may result in an overall decrease of mortality from PCa. Large-scale 
prospective screening studies are underway to test, whether this promise holds true 7,38. PSA 
serum level at the time of diagnosis is also considered a prognostic marker 39,40. PSA levels 
are also monitored for early detection of recurrence after therapy (surgery, radiation, or 
androgen withdrawal) 41.  
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1.4. Therapy of prostate cancer: 
1.4.1. Localized prostate cancer  
Localized prostate cancer can be treated with a curative intent (TMN stage T1&2). Radical 
prostatectomy is suggested to patients with clinically organ confined disease, a life 
expectancy of 10 or more years but no surgical contraindication 42. Radiation therapy provides 
an alternative to radical prostatectomy. The major side effects of these therapies include 
urinary incontinence and impotence. The incidence of these side effects has decreased in the 
past years due to technical improvements and new medical therapies. Watchful waiting can be 
an appropriate choice in selected patients in order to avoid overtreatment in slowly growing or 
clinically silent prostate cancers 7. In this approach, patients with early stages of PCa remain 
untreated but are carefully monitored for progression of disease. This strategy should be 
considered in case of focal prostate cancer with not more than one single focus of non high-
grade cancer in the prostate biopsies, and in patients in whom the natural life expectancy is 
lower than the expected benefit that may be achieved by aggressive therapy. Such patients 
may not benefit from aggressive therapy but experience a reduction of quality of life due to 
the side effects.  
 
1.4.2. Locally advanced PCa 
Locally advanced PCa refers to a tumour that is no longer confined to the prostate gland but 
has not yet metastasised to regional lymph nodes nor to more distant sites. The treatment 
options are palliative surgery, radiotherapy and androgen suppressing therapy. Radical 
prostatecomy is usually not performed in patients with clincial evidence of non organ 
confined disease, since cure can only rarely be achieved in these patients. 
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1.4.3. Metastatic prostate cancer 
Unfortunately, despite early diagnosis, still many PCa progress to metastatic disease. 
Androgen ablation is the standard therapy of these cancers Since androgens are the main 
growth and survival factors in prostate cancer withdrawal of androgens reduces the tumour 
size due to cellular death and decreased proliferation in androgen dependent prostate tumours 
43. Androgen withdrawal can be achieved by classical orchiectomy or pharmaceutically. 
Pharmaceutical suppression of testosterone production may be accomplished with the use of 
estrogens, antiandrogen, and agonists and antogonists of luteinizing hormone-releasing 
hormone (LHRH). Today, orchiectomy and LHRH agonists are most commonly used. LHRH 
agonists effectively reduce testosterone to castration levels by repression of the hypothalamic 
– pituitary – gonadal axis. Initially, almost all prostate cancer patients respond well to 
androgen withdrawal with a reduction of tumor size and alleviation of symptoms 44.  
 
1.4.4. Androgen independent (“hormone refractory”) prostate cancer (AIPC) 
Initial clinical response to androgen withdrawal is almost inevitably followed by progression 
towards androgen independent growth after a few months or years with progressive clinical 
deterioration and ultimately death 44. These androgen independent prostate cancers (AIPC) are 
characterized by the lack of sensitivity to any type of hormonal manipulation in the presence 
of androgen deprivation 45. For decades, no therapeutic option was available to prolong 
survival in these advanced cancers. Recently, two large phase 3 trials have demonstrated an 
overall survival advantage for patients treated with docetaxel-based regimens as compared to 
the best standard of care 46,47, and other novel therapeutic approaches are under investigation 
48. 
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1.4.5. Molecular mechanisms of androgen independence 
Androgen independence may be either complete independence of androgens as growth 
factors, or it may be tolerance of the low androgen levels present after androgen withdrawal 
therapy. Although the tumour is independent of androgens at high physiological 
concentrations, the tumour cells may still dependent on activity of the androgen receptor. 
There are several mechanisms of aberrant activation of androgen receptor. Gene amplification 
of the androgen receptor (AR) has been found to induce increased gene expression 49. As a 
consequence, lower levels of residual androgens, which are still present after androgen 
withdrawal therapy, may trigger activation of the androgen receptor 50. A second mechanism 
is mutations of the androgen receptor. These mutations may either increase affinity to 
androgens, or reduce specificity of the androgen receptor allowing estrogens, other steroids or 
even antiandrogens to bind and activate the androgen receptor 51-53. A third possibility is 
ligand independent activation of the receptor by intracellular signalling pathways. One 
prominent pathway which is involved in androgen independent activation of the androgen 
receptor is the ErbB2 induced activation of RAS/ ERK1/2 MApK pathways and PI3K/ AKT 
pathways 54-57. PTEN represses activity of the androgen receptor and cell proliferation 58. 
Thus loss of PTEN function may therefore facilitate tumour growth. Indeed, PTEN mutations 
and gene deletion are common in specimens from patients with advanced and hormonally 
treated prostate cancer 59. 
Also IL-6 dependent activation of MAPK and Stat3 pathways may lead to ligand independent 
activation of the AR 60. Interestingly increased IL-6 serum levels have been reported in 
prostate tumour patients 60. Similar results have been obtained with other growth factors such 
as the keratinocyte growth factor and the insulin-like growth factor-1 61. 
In addition, complete bypass of androgen receptor pathway is possible, though this seems to 
be less common 62,63. For example, there is evidence that overexpression of the apoptosis 
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inhibior Bcl-2 and neuroendocrine differentiation might provide growth advantage to prostate 
cancer cells under hormone withdrawal 64.  
 
1.4.6. Molecular genetics of prostate cancer  
Since cancer is often based on genetic alterations, the detection of chromosomal changes can 
pinpoint critical genes and highlight mechanisms of cancer development and progression. 
Comparative genomic hybridization (CGH) is a technique, which allows screening the whole 
genome for DNA sequence copy number alterations 65. Previous CGH studies have revealed 
several frequent chromosomal alterations in prostate cancer including loss of 8p, 13q and 16q, 
and gain of 8q 66-70. CGH is especially instrumental for pinpointing chromosomal loci that can 
undergo DNA amplifications 71. CGH has lead to the identification of more than 30 
previously unknown amplification sites in various tumor types 71. High-level amplifications 
can highlight genomic sites containing activated oncogenes with potential prognostic and 
therapeutic importance. This has been exemplified by the amplification of the HER2 gene in 
breast cancer. The HER2 status has become a routinely used predictor for therapy response to 
antibody-based therapy against the HER2 receptor 72.  
In prostate cancer, the discovery of androgen receptor (AR) gene amplification provides an 
example how a genome-wide survey, followed by a focused study at one chromosomal site 
led to the identification of a novel mechanism of prostate cancer progression, and to a marker 
for improved prediction of therapy response. After the identification of an amplification site at 
Xq11.2-q12 in 20-25% of hormone-refractory prostate cancers the AR was identified as the 
most likely target of this amplicon by fluorescence in situ hybridization using gene-specific 
DNA probes 50,66. AR amplification has only been found in prostate cancer and is almost 
exclusively restricted to hormone-refractory disease 50. AR amplification is likely to enable 
the tumors to maximize the effect of the remaining low levels of adrenal-derived testosterone 
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after orchiectomy by increasing the number of AR density in the tumor cells 73. Accordingly, 
AR amplified hormone-refractory prostate cancers have been shown to better respond to 
second-line total androgen blockage than tumors without AR amplification 74. Other high-
level gene amplifications have been reported in advanced prostate cancers 66,70,75. They 
include the prostate stem cell antigen (PSCA), RAD21 and KIAA0196 at 8q24 76,77, the p40 
subunit of eukaryotic translation initiation factor 3 (eIF3) at 8q23 78, and Cyclin D1 79 and 
INT2/FGF3 at 11q13 80. The chromosomal region 3q25-q27 was also frequently gained in 
prostate cancer by CGH, and subsequent comparative PCR analysis showed amplification of 
several genes in this region including SOX1, IL12A, SLCA2, and MDS1 81. 
 
1.4.7. 10q22 Amplification 
Amplification at 10q22 has been reported in prostate cancer82, osteosarcoma83, bladder 
cancer84, non-small cell lung carcinoma85, and breast cancer86. Especially in prostate cancer 
the 10q22 amplification was only found in late stages of the disease82. Interestingly, there is a 
frequent deletion observed at 10q (most likely q23-25) 82,87. This region comprises the 
prominent tumour suppressor PTEN, suggesting that deletion of 10q is most likely driven by 
deletion of this gene87. Originally the amplification at 10q22 was discovered in a comparative 
genomic hybridisation (CGH) screening approach in prostate cancer82. The amplification was 
subsequently mapped using yeast artificial chromosomes (YAC) as FISH probes (pers. 
Comm. L. Bubendorf) in the cell line PC-3. The mapped region spanned more than 16 Mb. It 
showed an amplification followed telomerically by a reduction of copy number (deletion).  
 
1.5. Goal of the study 
The goal of the study was to identify a gene that drives the amplification at 10q22 in clinical 
prostate cancer. To achieve this, we planned to screen the region for a peak of amplification in 
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order to pinpoint putative amplification target genes. The greatly increased gene dosage in 
case of amplification typically leads to increased gene expression, which could uncouple high 
gene expression from cellular regulation 88. In a second approach, genes mapped to 10q22 by 
the genome sequencing project were assayed in a real time PCR for comparison of gene 
dosage and expression. We compared gene expression of the model cell line PC-3, which 
contains an amplification at 10q22, with not amplified control cell lines (BPH-1, LNCaP, 
CWR22R). By taking the results of these two approaches we expected to narrow the selection 
of candidate genes. Considering known biochemical and cell biologic properties of these 
candidates, a hierarchy would be established to assay the genes on cellular levels for 
oncogenic properties. Ideally, experimental modulation of the activity if the candidate gene 
protein would response in altered growth rate of the model cell lines. 
 
1.6. Potential amplification target genes  at 10q22  
1.6.1. KCNMA1 (Large-conductance Ca 2+-activated potassium channel) 
We describe this gene in more detail than the other genes at 10q22 since it was subsequently 
selected as the major target of our project. 
KCNMA1 encodes for the pore-forming α-subunit of the BK channel, also referred to as 
Maxi K+ channel. BK channel is assembled from 4 large α-subunits that build the K+ pore. 
This assembly is a fully functional BK channel that allows K+ currents of 100-300pS 
inducing hyperpolarisation of the cell 89 It contains a voltage sensor in the transmembrane 
domain, which induces opening of the channel in response to depolarisation of the membrane. 
Additionally, it includes a intracellular calcium sensitive domain (c-terminus) 90. The gene 
KCNMA1 covers 0.7 Mb at the genomic locus 10q22 91. It contains 27 exons. The current full 
length cDNA published spans >11kb of sequence 92. Only the first 3730 bases are considered 
to contain the coding sequence. The full length α-subunit has a molecular weight of 130 kD. 
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One to four regulatory ß-subunits may associate to this complex of 4 α-subunits 93. These 
proteins are encoded by four individual genes named KCNMB1-4 94-98. These subunits affect 
the membrane potential that causes opening of the channel and provide interaction domains 
for binding of ligands. For example, iberiotoxin (ibtx) is a peptid toxin that specifically 
interacts with the BK channel in a competitive manner 99. The regulatory ß 1 subunit allows 
interaction with and blocking by ibtx, whereas expression of the ß 4 subunit provides 
resistance against ibtx 100,101. 17 ß -estradiol has been shown to interact with the extracellular 
domain of the BK channel, most likely through the ß 1 subunit 102. Binding of 17 ß -estradiol 
and structurally related molecules such as tamoxifen, induce activation of the channel 102. 
Activity of the BK channel may be influenced by alternative splicing 91. For example, 
inclusion of the stress regulated exon (STREX) causes the protein kinase A (PKA) to inhibit 
activity of the BK channel, whereas removal of the STREX exon causes PKA to activate the 
channel 103. A second site of alternative splicing generates a α-subunit that contains a 
dominant motif that causes retention of the channel at the endoplasmatic reticulum.104. This 
splice variant may provide insights into molecular mechanisms that cause cytoplasmatic 
localisation of the BK channel in presence of serum and allows translocation to the cellular 
membrane in response to serum starvation 105. Interestingly expression of BK channel has 
been shown to peak in G1 106. Surprisingly, cells arrest in S-phase, rather than in G1 phase, 
when BK channel activity is inhibited 105. Consistent with these data, it has been shown that 
BK channel activity may contribute to the maintenance of DNA synthesis by increasing 
mitogen-induced increase of intracellular Ca(2+) concentration 107 
 
Taken together, the BK channel system provides a collection K+ channels with distinct 
molecular properties from which a cell may select the subpopulation that fits its needs best.  
Activity of the BK channel has been found to be crucial in regulation of vascular tone, 
neuronal excitability, neurotransmitter release, endocrine function, innate immunity, and 
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hearing 108-112. In addition, functions in regulation of cell size and cell survival are suggested . 
Interestingly, a mouse strain containing genomic deletion of KCNMA1 is viable and fertile 
113. 
1.4.2. Other Genes at 10q22 with a possible role in cancer progression 
VDAC2 (voltage dependent anion channel 2): VDAC2 encodes one of the two human 
isoforms of the voltage dependent anion channel 114. This may bind to and inactivate Bak 
114,115. Dispalcing BAK from VDAC2 by tBID, BIM or BAD enables oligomerisation of BAK 
and thereby induces apoptosis 115. In addition, overexpression of VDAC2 protein has been 
shown to inhibit apoptosis 115.  
 
PLAU (uPA, urokinase plasminogen activator): PLAU has been linked to carcinogenesis 116. 
uPA is a extracellular protease involved in matrix remodeling, which might facilitate 
metastasis 117. Binding of the urokinase activator to its receptor, uPAR, may trigger a Ca2+ 
releasing intracellular signaling cascade 118. Hypothetically, this activates other Ca2+ 
regulated proteins at 10q22 including the BK channel Calcineurin, and Calmodulin 
Dependent Kinase 2 (CamK2). PLAU has previously been suggested as an amplification 
target at 10q22 in prostate cancer 119. Both pharmacological inhibition and molecular knock 
down by siRNA has been shown to reduce matrix invasion of uPA expressing cells119,120. 
Inhibition of uPA activity with specific inhibitors has been shown to reduce growth of 
prostate cancer xenografts121 
 
RAI17 (Retinoic acid-induced gene 17): This gene was not considered in the initial planning 
of our study, as it was mapped to 10q22 only in the year 2003 122. RAI17 interacts with the 
AR as shown by cotransfection and immunoprecipitation in simian kidney cell lysates122. A 
strong intrinsic transactivation domain was identified in the C-terminal proline-rich region of 
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RAI17. In human prostate cancer cells, RAI17 augments the transcriptional activity of AR. 
Moreover, RAI17 colocalizes with AR and SMALL UBIQUITIN-LIKE MODIFIER 1 
(SUMO1) at replication foci throughout S phase and is capable of enhancing attachment of 
SUMO to the AR in vivo. Studies using sumoylation-deficient AR mutants suggested that the 
augmentation of AR activity by RAI17 is dependent on the sumoylation of the receptor. 
These data suggest that RAI17 is a coregulator of AR122. Several other androgen coactivators 
such as TIF2 or SCR1 or AIB1 have been suggested to play an active role in androgen 
independent growth of PCa. It is assumed that overexpression of these factors might enhance 
AR response to low levels of androgen or broaden specificity of the AR similar to AR 
mutations. This might allow activation of transcription and cellular growth by AR in the 
setting of castration 49. Thus RAI17 qualifies as another very interesting amplification target 
at 10q22.  
 
CAMK2G (Calmodulin Dependent Kinase 2 gamma): CAMK2G encodes a catalytic subunit 
of the Calmodulin Dependent Kinase (CamK2) 123. CamK2 has diverse roles in virtually all 
cell types and it is regulated by a plethora of mechanisms. Some of these functions may 
provide growth regulatory stimuli to the cell. For example, CamK2 directly interacts to and 
phosphorylates Raf1, which provides a link between Ras/Raf/Erk and CamK2 pathways124. 
This pathway leads survival and proliferation of the immortalised thyroid cell line TAD-2 in 
response to interaction to fibronectin 125,126. Recently, CAMK2G has been shown to be 
involved in regulation of the assembly of the mitotic spindle 127.  
 
PPP3CB (Protein phosphatase 3, catalytic subunti, calcineurin B): PPP3CB encodes the ß-
isoform of the catalytic α-subunit of the protein phosphatase 3 128. Calcineurin, i.e. protein 
phosphatase 3 is assembled from the catlytic α-subunit, a regulatory ß-subunit and 
calmodulin129. The main function of calcineurin is dephosphorylation of the transcription 
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factor nuclear factor of activated T-cells (NFAT), which allows translocation of NFAT to the 
nucleus and transcriptional activity. NFAT regulates activation of T-cells. So far, calcineurin 
was mostly studied in immunology as it is the target for the immunosuppressive therapy with 
cyclosporin A. Calcineurin B is also involved in development and function of the nervous 
system, cardivascular function, signalling in sceletal muscle, and angiogenesis 129. Inhibition 
of calcineurin has also been shown to prevent VEGF induced migration and angiogenesis. 
Calcineurins might also play a role in cancer, although the detailed mechanisms remain to be 
elucidated. α and β isoforms of calcineurin A (catalytic subunit) have been found to be 
expressed at a  significantly higher level in colon cancer as compared to benign tissue 130. 
Calcineurin has also been found to increase expression of Matrix-Metalloproteinase 2 
(MMP2) 131. Calcineurins have a much higher affinity for Ca2+ than CamK2. Thus, it is 
assumed that calcineurins respond to long term low-level increases of Ca2+, while CamK2 is 
assumed to respond to short term high level increases of Ca2+ concentration (spikes) 132,133. 
 
MYST4 (Morf): MYST4 encodes a histone acetyl transferase 134 and has been implicated in 
development of leukaemia by structural and functional interaction with Runx2 135.  
 
ANX7 (Annexin A7, Synnexin): AnxA7 encodes a membrane associated protein that is 
involved in membrane fusion and may also act a voltage dependent Ca2+ channel 136,137 
Transfection of the wild type gene into human prostate cancer cell lines (LNCaP and Du145) 
leads to reduced tumour growth and reduced matrix invasion 138. In addition, expression is 
reduced in metastatic and locally recurrent Pca. In addition, tumour-suppressor properties of 
Anx7 have been demonstrated in Anx7 (+/-) mice 139. Thus, Anx7 is unlikely to be an 
amplification target at 10q22. These data from prostate cancer contrast with data from breast 
cancer, where overexpression of Anx7 has been suggested to be involved in metastasis 140.  
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PSAP: Prosaposin (PSAP) is a precursor of 4 saposins and has growth- and invasion-
promoting activities 141,142. Besides PLAU, PSAP is another gene that has recently been found 
to be amplified in PC-3 and some advanced prostate cancers 143. Prosaposin has been reported 
to activate p42/44 and SAPK/JNK signaling pathways of MAPK and to upregulate expression 
of PLAU/PLAUR in prostate cancer and stromal cells 142. This makes PSAP an interesting 
putative amplification target gene. PSAP was not taken into further consideration in our 
project because it is located at 73.2-73.3 MB on chromosome 10q22.1, which was not within 
our selected region of interest.  
 
1.4.3. Other Genes at 10q22 with no apparent role in cancer  
SFTPA1& SFTPA2 (surfactant, pulmonary-associated protein A1&2):Pulmonary surfactant is 
a phospholipid-protein complex that serves to lower the surface tension at the air-liquid 
interface in the alveoli of the lung 144,145 It is essential to normal respiration 146,147. Inadequate 
amounts of surfactant at birth, a frequent situation in premature infants, results in respiratory 
failure148.  
Polr3a (polymerase RNA III polypeptide A): This gene encodes the largest subunit of the 
human RNA polymerase 3 149. So far, there is no evidence for a cancer related function of 
Polr3a.   
RPS24 (ribosomal protein S24): This gene encodes the 40S ribosomal subunit protein S24 150. 
It is organized into 6 exons and is differentially spliced to yield 2 isoforms, S24a and S24c, 
that are present at varying ratios in different tissues 151. 
DUSP13 (dual specificity phosphatase 13): This gene has only recently been identified and 
allocated to 10q22. It encodes two dual-specificity protein phosphatases (DSPs) that are 
involved in postnatal development of specific tissues including including testis and skeletal 
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muscle152,153. Interestingly, the DUSP13 locus is the first gene from which two distinct 
proteins of the same family are expressed using alternative open reading frames153.  
ADK (Adenosine kinase): ADK catalyzes the transfer of the gamma-phosphate from ATP to 
adenosine, thereby serving as a potentially important regulator of concentrations of both 
extracellular adenosine and intracellular adenine nucleotides 154. No cancer related properties 
have been reported.  
SEC24c: In yeast, the Sec23-Sec24 complex is a component of coat protein II (COPII)-coated 
vesicles that mediate protein transport from the endoplasmic reticulum. SEC24C is one of 
several mammalian proteins that show structural and functional homology to yeast Sec24 
155,156.  
NDST2 (N-Deacetylase/ N-sulfotransferase 2): N-deacetyl/ N-sulfotransferase 2 catalyses the 
initial step in the processing of heparin polymerase to heparin sulphate or heparin 157. 
Targeted disruption of the mouse Ndst2 gene by homologous recombination suggest an 
essential function in mast cells 158,159.  
VCL (Vinculin): Vinculin encodes a cytoskeletal protein that crosslinks integrins and E 
Cadherins to F-actin 160,161 suggesting a function in cell adhesion. Vinculin has been 
demonstrated to inhibit cellular motility and apoptosis 162. The exact mechanism of how 
vinculin regulates apoptosis is unclear. However, it has been shown that vinculin allows 
stabilisation of PTEN protein 163. In addition vinculin null (vin-/-) cells show upregulated 
activity of extracellular signal-regulated kinase (ERK) 162. These data may explain 
observations of tumour suppressor properties of vinculin in SV-40-transformed Balb/c 3T3 
cells 164.  
MOYZ (Myozenin): Myozenin is a protein that localizes to the z-line of skeletal muscle 165. 
Expression was found to be highest in skeletal muscle. Until today no other function for 
myozenin have been reported. 
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There is also a number of genes at 10q22 from which no functional data are available, 
including ZNF503 (zinc finger protein 503), COMTD1 (catechol-O-methyltransferase domain 
containing 1), DUPD1 (dual specificity phosphatase and pro isomerase domain containing 1), 
SAMD8 (sterile alpha motif domain containing 8), AP3M1 (adaptor-related protein complex 
3, mu 1 subunit), FUT11, KIAA0913, and CHCHD1 (coiled-coil-helix-coiled-coil-helix 
domain-containing protein 1). 
 
Taken together, different genes with oncogenic properties in prostate reside at 10q22. This 
suggests that several genes, rather than just one single gene, might drive amplification at 
10q22. This model fits with theories of operon like organisation of the human genome 166. It 
has previously been shown that genes that are expressed under the same conditions are 
frequently colocalised to one genomic region 167. However a few cases of clusters of 
functionally related genes are known, for example the globin gene cluster or the hox gene 
cluster. This colocalisation in a distinct region of the genome would facilitate regulation of 
gene expression by means of chromatin organisation 167. In a simplistic view, activation of 
one given cellular pathway would only require activation of a limited number of genomic 
regions rather than the whole genome. In this context, it is highly interesting that three of the 
proteins encoded in the amplified region at 10q22 are regulated by Ca2+: Calcineurin, 
CamK2 and the BK channel. Also PLAU might be a part of this group because it may trigger 
a signalling cascade leading to intracellular increase of Ca2+ 118. 
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2. Results 
2.1. Amplicon mapping: BAC FISH on 10q22 TMA reveals no distinct peak of amplification 
In a previous analysis, the region of interest at 10q22 had been defined by mapping a YAC 
contig onto the human genome sequence published on www.ensemble.org. This contig was 
used to analyse the amplicon of PC-3 providing a first scaffold of the 10q22 amplification 
profile in PC-3. The two BACs RP11-464F9 and RP11-137H2 were selected as borders of the 
region of interest. Currently, these BACs are mapped to 75.1Mb and 82.2 Mb, respectively. 
The mapping process lead to the selection of a BAC contig, which contains 70 individual 
BACs (Fig. 1A). It covers 7 Mb of genomic sequence. Sequence data of the BAC were 
obtained and aligned in order to verify the contig. The sequencing software was not able to 
align the BAC into one contig. Overlapping of the small contigs retrieved from alignment was 
manually verified confirming that the selection covers one large contig. The BACs were 
obtained from the Sanger Centre (Cambridge, UK). We chose BACs as FISH probes rather 
than much larger YACs. BACs allow much higher resolution of the amplification profile, 
which may lead to a much more specific selection of amplification target genes.  
When this study was initiated, 9 genes were mapped to the region of interest. They included 
Annexin 7 (ANX7), Calcineurin 3B (PPP3CB), the calcium/calmodulin-dependent protein 
kinase (CaM kinase) II gamma (CAMK2G, KCCG_ Human), urokinase activator (PLAU), 
Vinculin (VCL), Adenosinekinase (ADK), monocytic leukaemia zinc finger protein related 
(MORF, MYST4), potassium channel, calcium activated, large conductance subfamily M, 
alpha member 1 (KCNMA1), and discs, large homolog 5 (DLG5) (Fig 1A). Thus, these genes 
were selected as first candidate genes. The evaluation of the amplification profiles by FISH 
did not reveal the expected anatomy of the 10q22 amplification. The overlay of all 
amplification profiles obtained from the 10q22 TMA showed a flat profile with no distinct 
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Figure 1: 10q22 Amplification. (A) The region of interest was defined between the BAC RP11-464f9 and 
RP11-137H2. The numbered bars indicate contigs assembled by the sequencing software. These contigs overlap 
to one large contig. Currently the region of interest is mapped between 75.1 Mb and 82.2 Mb on chromosome 
10 (source: ensemble.org). 
(B) Amplification profile of the 10q22 amplicon. In a series of 12 clinical human PCa biopsies there was no 
distinct peak of amplification. In addition the cell line PC-3 (amplified at 10q22) and control cell lines BPH-1 
JCA-1, CWR22R (all not amplified) were included. Amplification ratio= 0 indicates that this FISH probe could 
not be evaluated in this case. 
Y axis: amplification ratio = average of Bac FISH probe signals/ average of centromer 10 (CEP 10) probe 
signals 
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peak of amplification (Fig 1B). Thus, this experiment did not allow narrowing down the 
selection of candidate genes. However, there was a region with a tendency towards higher 
amplification ratios next to the BAC RP11-162M1 and RP11-325D15. A second region of 
higher amplification was located at the BAC 182L21 However, these differences were small. 
There are no genes that have been mapped to the BAC RP11-162M1 and RP11-325D15, yet. 
Also, there is no known gene mapped between these to BAC except a predicted transcript 
named CJ011_HUMAN. So far, no function has been ascribed to this transcript. The gene 
KCNMA1 resides 0.4Mb to the telomeric side of RP11-325D15. Similarly, there is no known 
 
Figure 2: FISH probe RP11-428P16 covering KCNMA1 genomic sequences. 
(A) Hybridisation on human reference cell lines shows specificity of the FISH probe. Metaphase chromosomes 
of a single cell show hybridisation to the 2 chromosomes 10 and no hybridisation to other chromosomes. 
Chromosome 10 is highlighted by hybridisation of a probe specific for its centromer. 
(B) Hybridisation on BPH-1 shows the normal ratio of 2 centromers per cell and 2 probe signals near by. 
(C) Hybridisation on PC-3 shows amplification of the FISH probe (arrows). Amplification is seen as a cluster of 
probe signals next to the centromer 10 signals. PC-3 is polysomic for chromosome 10 (not shown in this 
image). 
(D) Hybridsation on a human PCa with a ration of 2/ 2 (FISH probe/ centromer). 
(E+F) Hybridisation on two human PCa with amplification seen as cluster of probe signals (arrows) 
The figure shows false colour images. Blue: DNA (DAPI stain), green: FISH probe RP11-428P16, red: 
centromer 10 probe (CEP10, Vysis) 
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gene mapped to the BAC RP11-182L21. Next to this BAC there is the gene SFTPD. The 
BAC RP11-428P16 was selected for further study because it contains genomic sequences of 
the gene KCNMA1. In the mean time, two interesting genes VDAC2 and RAI17 have been 
mapped to 10q22. VDAC2 locates to the BAC RP11-399K21, and RAI17 is close to the BAC 
RP11-342M3.  
 
2.2. Expression of 10q22 genes in model cell lines 
In addition to FISH analysis, we performed a gene expression analysis of the selected 
candidate genes located at 10q22 using a LightCycler based RT PCR assay. For this 
experiment we obtained 5 human cancer cell lines including PC-3, LNCaP, BPH-1, 
CWR22R, and JCA-1. In the mean time JCA-1 has been shown to be a bladder cancer cell 
Figure 3: Expression of genes at 10q22 in human PCa cell lines. 
Highest relative expression was found for PLAU when PC-3 was compared to LNCaP and CWR22R but not  
The figure shows expression of LNCaP, BPH-1, CWR22R, and JCA-1 compared to PC-3. Values > 0 indicate 
increased expression in PC-3, values < 0 indicate reduced expression in PC-3. y axis: numbers of PCR cylces 
corrected for expression of GPDH. 
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line by means of cytogenetics 168. Thus, data obtained for JCA-1 were considered of reduced 
significance for this project.  
All cell lines except CWR22 grew readily in Optimem +10% FCS. These surface adhering 
cells accept non-coated plastic (Falcon cell culture flasks) as substrate. In contrast to PC-3, 
LNCaP, and BPH-1, CWR22 required higher cell density for rapid growth.  
Analysis of mRNA expression by LightCycler RT-PCR revealed that all of the selected genes 
were expressed at a higher level in PC-3 as compared to the control cell lines, with the 
exception DLG5 and MORF (BAC RP11-312P12) (Fig 3).  
Among all tested genes, PLAU was most strongly expressed in PC-3 as compared to LNCaP 
and CWR22R. However, there was no increased expression of PLAU in PC-3 relative to 
BPH-1 and JCA-1. In case of a amplification target gene, one would ideally expect a more 
consistent association between gene amplification and overexpression.  
KCNMA1 showed the second highest expression in PC-3, although the difference to other 
genes was small. Importanly, all of the 4 control cell lines expresses KCNMA1 at a lower 
level than PC-3. Expression of PTEN was assayed as a reference, as it is known to be deleted 
at 10q24 in PC-3. As expected, expression was markedly lower in PC-3 as compared to the 
control cell lines (Fig 3).  
Although mRNA expression analysis did not clearly highlight a putative amplification target,  
the consistent association between amplification and overexpression of KCNMA1 made it the 
most interesting candidate for further analyses. The experiment allowed excluding DLG5 and 
MORF as putative amplification target genes. 
 
 27
 
2.3. FISH on a prostate progression array 
Next we assayed the prevalence of 10q22 amplification in clinical prostate cancer. For this 
assay, the BAC RP11-428p16 that includes genomic sequences of the gene KCNMA1 was 
selected as a FISH probe. We screened a prostate progression TMA that had been built from 
587 individual cases of PCa and 25 controls. In total 262 (45%) samples could be evaluated. 
A case was considered not evaluable if there was either no probe signal, or no CEP 10 signal, 
or if there was too high background fluorescence precluded clear distinction of specific from 
non specific signals.  
These data confirmed the previous observation that amplification at 10q22 prevails only in 
late stages of prostate cancer (Table 1). Amplification was found in T 3/4 stage cancer (2 of 
10 cases), distant metastases (7 of 47), and hormone refractory cancer (12 of 45). Surprisingly 
there were no amplified cases within the 17 regional lymph node metastases (0 of 17). As 
expected, there were no amplifications in benign prostatic hyperplasia (33 cases), high grade 
PIN (32 cases), and the early stage prostate cancers at stage T1 (43 cases) and T2 (62 cases). 
KCNMA1 amplification KCNMA1 
amplification 
category Number of cases 
(n) (%) 
Benign prostatic 
hyperplasia 
33 0 0 
High-grade PIN 32 0 0 
T1a/b 43 0 0 
T2 62 0 0 
T3/4 10 2 20.0 
Lymph node 
metastases 
17 0 0 
Distant metastases 47 7 13.0 
Hormone-refractory 
local recurrences 
45 10 22,2 
 
Table 1: Prevalence of KCNMA1 amplification in prostate cancer. FISH analysis of 298 specimens on a 
prostate specific tissue microarray (TMA). The BAC RP11-428P16 was used as KCNMA1 specific probe and 
the centromeric probe for chromosome 10 as a reference. Amplification was defined as a ratio between gene 
and reference of ≥ 2. BPH = benign prostatic hyperplasia, PIN = prostatic intraepithelial hyperplasia, T1a/b = 
incidentally detected prostate cancer in transurethral resection for presumed BPH, T2 = clinically organ 
confined prostate cancer treated by radical prostatectomy, T3/4 = clinically non-organ confined, locally 
advanced prostate cancer treated with palliative transurethral resection, LN metastases = pelvic or paraortal 
lymph node metastases. 
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(D) 
Figure 4: Modulation of BK channel activity in vitro. Impact of ibtx and estradiol on growth of PC-3, LNCaP, 
and BPH-1. 
(A) Growth of PC-3. PC-3 proliferates up to day 3. At day 4 the culture collapses as indicated by the high 
standard deviation at this time point. Ibtx reduces PC-3 cell numbers significantly but does not prevent 
proliferation. Y-axis: total number of cells per well. 
(B) Growth of PC-3 in response to ibtx and estradiol. Growth of PC-3 is significantly reduced by ibtx. Addition 
of estradiol does not changed growth of PC-3 significatly and does not override action of ibtx. 
(C) Growth of BPH-1 in response to ibtx and Estradiol. Growth of BPH-1 is not change in response to ibtx. 
Addition of Estradiol increased growth of BPH-1. Combination of estradiol and ibtx does not alter the growth 
rate as compared to the control.  
(D) LNCaP responds in a similar way as BPH-1, though not statistically significant. 
C: Control, I: Ibtx, E: 17b-estradiol, E+I: Combination of Estradiol and Ibtx. 
(B-D) y-axis: virtual growth rate k from the hypothetical growth curve A(t)= A0*ekt. A(t): number of cells at 
time t, A(0): number of cells at time 0, t: time in days. 
 
2.4. Modulation of BK channel activity affects growth of PC-3 and BPH-1 
In this assay we took advantage of the known fact that 17β-estradiol and Iberiotoxin (ibtx) 
modulate the activity of the BK channel. 17β-estradiol activates the BK channel by 
interaction with the β1 subunit. In contrast ibtx is considered a highly specific BK channel 
inhibitor. 
For this experiment a specialised medium formulation of Optimem + 10% Albumax was used. 
Although PC-3, LNCaP and BPH-1 grow well in Optimem + 0.4% Albumax (see Fig. 4a in 
case of PC-3) none of these cell lines adhere readily to the uncoated surface of Falcon 6 well 
0,0E+00
1,0E+05
2,0E+05
3,0E+05
4,0E+05
5,0E+05
6,0E+05
7,0E+05
8,0E+05
9,0E+05
0 2 3 4
days
nu
m
be
r o
f t
ot
al
 c
el
ls
K
I
1,05
1,1
1,15
1,2
1,25
1,3
1,35
1,4
1,45
gr
ow
th
 ra
te
1
1,05
1,1
1,15
1,2
1,25
1,3
1,35
1,4
gr
ow
th
 ra
te
Ι Ε Ε+ΙC 
1,15
1,2
1,25
1,3
1,35
1,4
1,45
1,5
1,55
gr
ow
th
 ra
te
Ι Ε Ε+Ι C
Ι Ε Ε+Ι C
 29
plates when seeded in this medium. As a consequence the cells were seeded in standard 
growth medium (Optimem +10% FCS). After one day, the medium was changed to Optimem 
+1%FCS. The next day, the medium was changed to Optimem+ 0.4% Albumax containing 
the drugs if needed. Thus, this protocol includes a step of serum starvation that may influence 
the results. However, since all samples in the experiment were equally treated we considered 
the influence of this protocol on the results to be of minor importance.  
The obtained data were used to calculate a virtual growth rate k from a hypothetical 
experimental growth curve A=A0*ekt. A and A0 were numbers of cells, t is time in days. There 
was a significant reduction of the growth rate of PC-3 in response to treatment with ibtx (Fig. 
4B). Although this experiment confirmed involvement of the BK channel in regulation of 
rapid growth of PC-3, the observed reduction of cell growth was relatively small. Ibtx treated 
PC-3 continue to proliferate at high division rate. In contrast to PC-3, growth of BPH-1 was 
not altered in response to ibtx (Fig. 4C). Taken together, the data suggest that PC-3 (in 
contrast to BPH-1) expresses a pool BK channel that is constitutively active at the conditions 
of growth in this experiment. 
 
Addition of 17β-estradiol to BPH-1 significantly stimulated growth of this cell line (Fig 4C). 
Importantly, the stimulation of growth induced by 17β-estradiol could be prevented by 
administration of ibtx. This finding suggests that 17β-estradiol induces growth in BPH-1 
through activation of BK channel (Fig 4C). In contrast growth of PC-3 was not stimulated by 
17β-estradiol (Fig. 4B). However, when estradiol and ibtx were added together the effect of 
ibtx was retained. Thus, in contrast to PC-3, BPH-1 may contains a pool of BK channels that 
are inactive at the growth conditions of this experiment but may be recruited to stimulate 
growth of this cell line.  
The response of LNCaP was similar to the response of BPH-1. However, the high variation of 
the raw data prevented the analysis of statistical significance of growth in LNCaP (Fig. 4D). 
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(B) 
Figure 5: Anti KCNMA1 siRNA in PC-3. 
(A) Reduction of KCNMA1 mRNA in response to anti KCNMA1 siRNA K1-4. Transfection of siRNA K1 and 
K2 reduced KCNMA1 mRNA levels to <20% when compared to non-transfected cells (c-si) or cells transfected 
with scrambled sequence RNAi (scr). Transfection of siRNA K3 and K4 reduced KCNMA1 mRNA levels to 
<50%. Figure is drawn to be relative to the expression in the control (c-si). Thus all 4 siRNA K1-4 significantly 
reduce KCNMA1 mRNA in PC-3. 
(B) KCNMA1- RNAi using all 4 active siRNA K1-4 has a pronounced inhibitory effect on PC-3 cell growth. Y-
axis shows total number of cells per well. 
C0: non treated PC-3, c-si: non-transfected cells, only transfection agent, scr: transfected with scrambled sequence 
RNAi, K1-4: transfection of siRNA K1-4. 
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2.5. siRNA 
SiRNA technique was applied to study the effect of specific knockdown of KCNMA1 
mRNA. The 4 individual siRNAs that were used target different regions of the mRNA. 
Interestingly, siRNA K2 targets a region that has been implicated in alternative splicing 169,170. 
SiRNA lead to a knockdown of KCNMA1 mRNA levels of 2-4 PCR cycles, which 
corresponded to a reduction of mRNA by 50-80%. Knockdown of KCNMA1 mRNA was 
achieved by all 4 siRNA molecules tested (Fig. 5A). Thus, all 4 siRNA could be used to study 
contribution of KCNMA1 to cellular growth of PC-3.  
Transfection of siRNA slightly reduced growth of PC-3 as compared to the negative control 
experiments. Both treating the cells with lipofectamine and - even more pronounced - 
transfection of inactive scrambled siRNA lead to a significant reduction of PC-3 cell numbers 
at day 3 after transfection (at day 3 c0 vs c-si: p=0,0238, c0 vs scr: p=0,0038, c-si vs scr: 
p=0,01743; Fig 5B), though PC-3 continued to grow rapidly. PC-3 cells that were treated with 
any of the active siRNA K1-4 grew very much slower than any of the controls (the p-value is 
equal or smaller than 0.001 for all combinations of controls versus the active siRNA at day 3; 
FIG 5B). Thus the toxic effect of the transfection is minor when compared to the effect of 
active siRNA. Notably, some proliferation was retained in siRNA treated PC-3 after siRNA 
transfection, though at a very low level (Fig 5B). Taken together, these data strongly suggest 
that the BK channel promotes rapid growth of PC-3, but it is most likely not essential to 
vitality. 
Interestingly, transfection with anti KCNMA1 siRNA had a reproducible effect on the 
phenotype of PC-3 after four days (Fig 6). The phenotype of untreated PC-3 was a spindle-
like, triangular to rectangular cell shape when grown in Optimem + 10% FCS (Fig 6 A-C). It 
readily adhered to the surface of the culture flask with little cells floating in the medium. 
Little or no cell to cell interaction seemed to be required for growth of PC-3 because most of 
the cells grew in an isolated manner with no contact to each other. Similarly, there was no 
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tendency to grow as nodules or other forms of cellular aggregates at low cellular density. 
Filopodia were frequently seen at the endings of the spindle. The siRNAs 1, 2, and 4 induced 
a similar phenotype. After siRNA treatment, the PC-3 cells spread towards a roughly 
rectangular shape (Fig 6D, E, and G). However, subtle differences of the phenotype were 
visible for these three siRNAs, making each phenotype unique. Astoningishly, siRNA K3 
treated cells looked completely different. These cells became longer and thinner as compared 
to wild type PC-3 cells (Fig 6F). This finding suggests that the action of the individual 
siRNAs may differ. Although non-specific action cannot be excluded, these siRNAs might be 
useful to understand more deeply the diverse function and regulation of the BK channel. 
However, this was beyond the scope of this study. 
Figure 6: Phenotype of PC-3 4 days after transfection of siRNA. 
(A) normal Phenotype of PC-3. The cells were not transfected with siRNA (c0). The cells show a typical spindle 
like phenotype. 
(B) The phenotype of PC-3 treated with transfection agent (c-si) closely resembles the phenotype of (A). 
(C) The phenotype of PC-3 transfected with scrambled sequence siRNA (scr) closely resembles the phenotype of 
(A). 
(D) Transfection of siRNA K1: PC-3 cells cover a much larger surface area and show a roughly rectangular cell 
shape. 
(E) Transfection of siRNA K2: PC-3 cells cover a much larger surface area and show a roughly rectangular cell 
shape. 
(F) Transfection of siRNA K3: PC-3 cells form a elongated spindle with reduced diameter and increased length 
as compared to (A-C) 
(G) Transfection of siRNA K4: PC-3 cells cover a much larger surface area and show a roughly rectangular cell 
shape. 
 
 33
 
LNCaP and BPH-1 were also treated with siRNA. As in PC-3, knockdown of KCNMA1 was 
verified by quantification of KCNMA1 mRNA. In BPH-1, the siRNAs K1 and K2 lead to a 
knockdown of mRNA of 4 and 2.5 PCR cycles, which corresponds to a relative reduction of 
10% and 23%, respectively (Fig 7A). siRNA K4 induced a reduction of only 1 PCR cycle, 
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(B) 
Figure 7: Anti KCNMA1 siRNA in BPH-1. 
(A) Relative reduction of KCNMA1 mRNA in response to anti KCNMA1 siRNA K1-4. Transfection of siRNA 
K1, K2, and K4 reduce KCNMA1 mRNA to 10%, 23%, or 50%, respectively, as compared to scrambled 
sequence RNAi (scr). The siRNA K3 reduces KCNMA1 mRNA to only 68% as compared to scrambled 
sequence siRNA. The y-axis shows relative expression of KCNMA1 as compared to transfection of scrambled 
sequence siRNA (scr). These data are corrected for expression of G6PD.  
(B) KCNMA1- RNAi using all 4 active siRNA K1-4 has an inhibitory effect on BPH-1 cell growth. Y-axis 
shows total number of cells per well. 
c-si: non-transfected cells, only transfection agent, scr: transfected with scrambled sequence RNAi, K1-4: 
transfection of siRNA K1-4. 
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and siRNA K3 had almost no effect with a reduction of only 0.3 PCR cycles, which is still in 
the range of experimental errors. This minor effect of K3 on BPH-1 was reproduced in 
repeated experiments.  
In BPH-1 there was a growth reduction of about 50% at day 4 after transfection all siRNA 
(Fig. 7B). Although the effect was much less pronounced than in PC-3, these data suggest that 
KCNMA1 is also involved in the growth of BPH-1.  
 
In the LNCaP cell line, stable PCR used for RT PCR could not be achieved, precluding 
reliable mRNA expression analysis after siRNA. We did not obtain specific PCR product 
using the standard PCR conditions. The reasons for this failure of PCR in LNCaP are not 
clear. Increasing the elongation time of the PCR from 15 sec to 2 min resulted in PCR 
products that are longer than the original fragments. As the same PCR protocols worked well 
for BPH-1 and PC-3 that were run in parallel, the inability to obtain appropriate PCR products 
in LNCaP might be related to the RNA properties of this specific cell line. Also, changing 
PCR conditions such as annealing or Mg2+ concentration could not solve this problem. Thus, 
LNCaP could not be used to test the effect of anti KCNMA1 siRNA on growth of cell lines in 
vitro because we could not verify whether or not siRNA reduces of KCNMA1 expression 
(data not shown). 
 
2.6. Western blotting 
Testing for specificity of the 3 commercially available anti-BK channel antibodies for 
specificity revealed bands of variable sizes for all antibodies irrespective of the type of lysis 
buffer. Among the 3 antibodies, APC-107 from Alomone Labs showed brightest signal and 
lowest background. These tests revealed a mobility shift assay, giving a unique banding 
pattern for each cell line (Fig. 8A). In PC-3 and BPH-1 a weak band of the size of the full 
length BK channel α-subunit is visible 
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Next, we assayed the knockdown of the BK channel α subunit in response to anti KCNMA1 
siRNA treatment in PC-3.  
The immunoreaction did not reveal any difference in band intensity for all assayed time points 
and all siRNAs tested as compared to the related controls (Fig 8B). Thus this experiment did 
not demonstrate reduced BK channel protein in response to siRNA.  
 
(A) 
 
 
(B) 
Figure 8: Western blot of BK channel from PCa cell lines. 
(A) BK channel of PC-3, LNCaP, and BPH-1 resolved on a 6% acrylamide gel. Each cell produces a distinct banding pattern 
when BK channel a subunit is resolved using the antibody APC-107 (Alomone labs). The bands show a weak band of full 
length of BK channel a subunit (indicated by arrow). Bands of lower molecular weight may represent degradation products 
of the BK channel  
(B) siRNA in PC-3. There is no difference in BK channel expression observed in response to siRNA, although knock down 
of KCNMA1 mRNA was measured (Fig 5a). 
The antibody was APC-107. The gel was a precast 4-12% acrylamid gel (Invitrogen). 
scr: transfected with scrambled sequence RNAi, K1-4: transfection of siRNA K1-4. 
 
2.7. KCNMA1 expression in human tumours using RT PCR: 
During the last few years fresh biopsy material from locally advanced prostate cancer was 
collected and stored at -70°C at the Institute for Pathology of the University Hospital Basel 
for molecular analysis including gene expression analysis. The estimated time frame from 
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surgical tissue removal to freezing ranged from 20 to 40 minutes. It is likely that some 
variable degree of RNA degradation occurs within this time span. For practical reasons, 
however, it is almost impossible to cut this time frame much shorter in a diagnostic setting of 
a pathology laboratory. From our series of fresh frozen specimens, we were able to identify 2 
individual human prostate cancers with KCNMA1 gene amplification by FISH to the frozen 
TMA. We compared mRNA expression of KCNMA1 from PC-3, 2 tumours with gene 
amplification, 7 tumours without gene amplification, and two cases of BPH. The tissue for 
RNA extraction was punched from blocks of frozen tissue. The tissue area was selected to 
contain maximal amount of the desired tissue avoiding surrounding stroma if possible. The 2 
tumors with KCNMA1 amplification did not have an increased expression of KCNMA1 as 
compared to the not amplified tumours (Fig 9). In contrast, the samples of BPH had increased 
expression of KCNMA1 up to the level of PC-3. Thus, we found no correlation between gene 
amplification and mRNA expression of KCNMA1 in human tumours.  
Figure 9: Expression of KCNMA1 gene products in human PCa and PC-3. 
The figure shows expression of KCNMA1 gene products in PC-3, 2 cases of BPH (1& 2), and 9 cases of human 
PCa (3-11). Amplified cases are cases 9 and 11. BPH has much higher expression of KCNMA1. Amplified 
cases do not show increased expression as compared to not amplified cases of PCa.  
Y-axis: Expression of KCNMA1 corrected for expression of the reference gene G6PD, in PCR- cycles. 
Increased values indicate increased relative expression of KCNMA1 
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3. Discussion 
3.1. Screening the Amplicon at 10q22 
Gene amplification is considered a critical mechanism of carcinogenesis in different tumour 
types 171. Prominent examples are amplification of ERBB2 in breast cancer and amplification 
of the androgen receptor (AR) in prostate cancer 50,172,173. In these cases amplification of the 
proto-oncogenes uncouples expression from cellular regulation, which leads to increased 
expression and uncontrolled activity of the proteins. In the case of ERBB2, increased 
expression leads to constitutive activation of the receptor tyrosine kinase and ERBB2 
dependent signalling174,175 Similarly, increased expression of AR allows activation of AR at 
the very low cellular concentration of androgens that remains after androgen withdrawal 50. 
Amplification allows activation of downstream pathways independently of proper external 
stimuli 49,176. Amplifications can pinpoint to genes with oncogenic properties. Thus, the study 
of amplified regions on structural and functional levels may lead to the discovery of novel 
oncogenes.  
It has repeatedly been shown that one amplicon can contain more than one amplification 
target gene that may contribute to selection. For example, co-amplification of GST-pi, INT2 
and HSTF1 has been described at 11q13 in breast cancer 177, and coamplification of GRB7 
and ERBB2 in Barrett’s carcinoma 178. 
 
3.2 Structure of the Amplification at 10q22 
In general, the structure of an amplicon, i.e. its profile, which is the ratio of amplification 
plotted on the scaffold of the human genome, is assumed highly predictive in the context of 
selection of amplification target 179-181. Accordingly, a first attempt was to screen the region at 
10q22 for a peak of amplification. The method of choice was fluorescence in situ 
hybridisation (FISH) because it allows a good compromise between relatively small probes 
(bacterial artificial chromosomes have an average length of 100-200 kb) and high throughput 
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when used on tissue microarray (TMA) 182. We used a specialised TMA that was enriched for 
prostate cancer with 10q22 amplification to define the amplification profile at 10q22 and 
narrow down its peak. 
Due to the flat profile of the amplification with no distinct peak, we were not able to further 
narrow down the initial selection of candidate genes (Fig 1B). This amplification shows 
relatively low amplification ratio and covers a large region of the genome of greater than 7 
Mb. Based on the existing amplification profiles as shown by comparative genomic 
hybridization in PC-3 and in previously analyzed clinical prostate cancers, we would have 
rather expected the presence of an amplification peak. The reasons for the absence of a 
distinct peak in our FISH analysis remain unclear. It could be that the Vinculin BAC probe 
that had been used to select amplified tumours for this specialized TMA was not optimal. 
Vinculin was not highly amplified and may reside close to the base of the amplicon. The 
amplification at 10q22 is large when compared to many other known amplifications. The 
factors that determine the size of an amplicon are not well defined but include physical factors 
such as the specific location of fragile sites. Fragile sites are known to favour amplification 
and determine the form and the boundaries of amplicons 183. Accordingly, recurrent 
chromosomal breakpoint at 10q22 has previously been observed to participate in deletion and 
translocation in several prostate cell lines including PC-3 184. Interestingly, the gene MYST4 
at 10q22 has been found to be involved in a translocation in a subgroup of acute myeloid 
leukaemia 185. 
In addition, one could speculate that the size of the amplicon increases as the number of 
selecting amplification target genes increases. Thus, a large amplicon such as the one at 
10q22 may contain several genes that jointly act as a selective force. This view is supported 
by previous CGH array data where two types of amplicons have been identified including 
large amplicons spanning up to several Mb of genomic sequence and small amplicons with 
only one or two genes 186.  
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Taken together, there are at least two forces that determine amplification: a region in the 
genome that is prone to genomic rearrangement, and positive selective forces that favour 
inheritance of the amplification such as oncogenes. Since these two forces cooperate to 
generate an amplicon, the selective force may not need to be located on the peak region, as 
long as it is included in the amplicon. 
 
3.3 Clinical Prevalence of Amplification at 10q22 in Prostate Cancer 
It has previously been shown that most amplifications in prostate cancer occur at late stages of 
progression but only rarely in localized cancers 187,188. For example, MYC amplification has 
preferentially been found in metastases, and androgen receptor is almost always restricted to 
advanced, androgen insensitive prostate cancer 50,75,187. Similarly, we found amplification of 
the BAC RP11-428p16 only in advanced stages of prostate cancer (Table 1). Chromosomal 
instability may be a prerequisite of amplification as it also develops during prostate cancer 
progression. The fact that amplification is absent or rare in earlier stages due to mechanistic 
reasons does not exclude a role of amplification target genes in carcinogenesis at this stage. 
Such genes may exert an effect on tumour growth and early progression in early stage 
tumours through lower level of expression due to low-level increase of gene dosage or 
through epigenetic mechanisms. 
 
3.4 KCNMA1 as putative amplification target gene. 
In this project we selected KCNMA1 for further studies based on the following pieces of 
evidence: 1. There is a consistent association between KCNMA1 amplification an mRNA 
overexpression in PC-3 and control cell lines in vitro (Fig2B,C, Fig 3). 2. KCNMA1 
amplification is present in a fraction of advanced prostate cancers in vivo, and 3. The known 
specific blocker ibtx and the activator 17β-estradiol were available for functional studies 
100,102. The fact that ibtx significantly inhibited growth of PC-3 strongly suggests that the BK 
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channel contributes to growth of PC-3 and that the channel is active at standard growth 
conditions (Fig 4). This finding is consistent with the results from previous studies on other 
cell lines and different K+ channels, where an involvement of K+ channels in carcinogenesis 
has been suggested 189-193. Importantly, the growth inhibitory effect of ibtx was restricted the 
PC-3 but absent in BPH-1 and LNCaP, which is in favour of a functional importance of 
amplification driven overexpression of KCNMA1. However, the growth stimulatory effect of 
17β-estradiol on BPH-1 and LNCaP could be blocked by ibtx suggest that BK channel may 
also be essential to the growth stimulation in these cell lines without KCNMA1 amplification. 
We assume that the growth stimulatory effect of 17β-estradiol in these cell lines is to a great 
part mediated through activation of the BK channel rather than by activation of steroid 
receptors 194. In addition our result suggests that both BPH-1 and LNCaP contain a pool of 
BK channels, which - in contrast to PC-3 -is inactive at standard growth conditions (Fig 4).  
 
3.5 Anti KCNMA1 siRNA suggests a role of KCNMA1 in rapid growth of PC-3 and BPH-1 
In order to further strengthen the data we performed anti KCNMA1 siRNA to knock down 
expression of KCNMA1 mRNA (Fig 5, Fig 7). This experiment lead to reduced growth of 
both PC-3 and BPH-1, suggesting that both cell lines require KCNMA1 expression for rapid 
growth. The positive effect of KCNMA1 mRNA knockdown in the non-amplified cell line 
BPH-1 may question the importance of KCNMA1 as amplification target. However, BPH-1 
has considerably lower KCNMA1 expression that may induce rapid growth if it is properly 
stimulated. Furthermore it contains a functionally different pool of BK channels than PC-3. It 
appears that a minimum level of KCNMA1 expression is required for rapid growth of these 
two cell lines, independent of amplification.  
It has recently been reported that K+ channels of intermediate K+ gating potential (IK 
channel) rather than BK channels are active in PC-3 195. This report, however, can not be 
compared to our data, because the authors performed the measurements in Ringer solution 
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whereas we used normal growth medium in our experiments. It is known that the type of fluid 
environment can greatly influence the properties of the cells 196,197. For example, it has been 
shown that the presence of serum growth factors in the medium significantly alters the 
membrane potential of the cells 198. This altered membrane potential modulates activity of 
voltage dependent K+ channels, such as the BK channel 199.  
 
In addition to functional changes we observed an interesting morphologic effect of siRNA in 
PC-3 but not in BPH-1 (Fig 6). All four siRNA molecules targeted against KCNMA1 mRNA 
resulted in a unique and reproducible phenotype in PC-3. This suggests that the phenotype is 
dependent on the siRNA molecule used. These individual phenotypes may be caused by a 
knock down of individual subsets of KCNMA1 mRNA that could be generated by alternative 
splicing. Thus, these phenotypes may reflect inactivation of different subsets of BK channels. 
However this remains hypothetic and needs to be studied in more detail. For example, it needs 
to be tested whether these phenotypes are not just side effects of the individual siRNA 
molecule without being related to specific knock down of KCNMA1.  
It is noteworthy that K2 targets a region of the BK channel that is obviously involved in 
alternative splicing (splice site 1) 169,170. If this siRNA targets only a subpopulation of the 
whole KCNMA1 mRNA, it might not only reduce BK channel expression but also alter its 
activation and deactivation kinetics. 
 
It is known that transfection of long double stranded RNA molecules can have unspecific 
effects. These effects can include a general block of gene transcription and induction of 
apoptosis in mammals 200,201. Such unspecific effects are unlikely in our study as the length of 
our siRNAs did not exceed 21 bp 202. Crosshybridization to RNA from other genes might be 
another cause of non specific effects of siRNA. Such crosshybridization was most unlikely in 
our study as blasting of the siRNA target sequences against the human genome did not 
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produce a specific hit besides the human KCNMA1 mRNA. Unspecific knockdown of genes 
due to undefined mechanisms of siRNA action is more difficult to control and not yet 
predictable for individual siRNAs . We used scrambled sequence siRNA as a well established 
control for this purpose. However, the use of specific controls may be more appropriate, i.e. 
siRNA with point mutations as compared to the active siRNA K1-4. Such specific controls 
are sometimes recommended to increase the reliability of the experiments. In contrast to 
random sequence controls they might better control unspecific action of the siRNA. 
Based on our current data it is not yet possible to decide whether or not KCNMA1 is an 
oncogene. However, the presence of gene amplification in advanced prostate cancer in vivo, 
the association between amplification and mRNA over-expression in cell lines, and growth 
effect of blocking KCNMA1 activity in vitro strongly suggest that KCNMA1 plays a role in 
the progression of prostate cancer. Nevertheless, we do not claim that KCNMA1 is a major 
player in a complex network of regulation of cellular growth, survival and other cancer related 
function. We rather believe that KCNMA1 contributes to growth by supporting general 
growth regulating functions of the cell.  
 
3.6 No correlation between amplification and overexpression in human prostate cancer 
Despite the line of experimental evidence that suggests KCNMA1 as a candidate 
amplification target at 10q22 in prostate cancer; there are data that question this hypothesis. 
Surprisingly, there was no correlation between expression and amplification in a limited series 
of human tumours (Fig 9). If true, these data would reject our hypothesis of amplification 
driven increase of expression of KCNMA1 in human tumours and suggest that the found 
association may be a clinically irrelevant property of prostate cell lines. However, the data are 
problematic in several ways. First, the number of cases (2 amplified cases, 10 controls) is too 
low to allow definitive conclusions. Quality of the RNA is another concern. The tissue 
specimens did not provide enough RNA for testing RNA quality prior to cDNA synthesis. 
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Although the material was frozen at -70°C immediately upon arrival at the institute for 
pathology, the time span from surgical removal of the tissue to the arrival at the laboratory 
may have been variable, with an estimated range from 20 to 40 minutes. Thus, it cannot be 
excluded that some of the RNAs were degraded 203. Taken together, the analysis of KCNMA1 
expression in clinical tumours and its association with gene amplification needs to be repeated 
under optimized condition with a higher number of tumours before we can draw final 
conclusions.  
 
3.7. BK channel activity is reduced in response to transfection of siRNA K2 
A major limitation of this study was the failure to demonstrate the effect of KCNMA1 mRNA 
knockdown by siRNA on protein expression (Fig 8B). Our experimental model assumes that 
RNA interference of KCNMA1 reduces activity of the BK channel due to reduced expression 
of the pore forming α-subunit after specific knock down of the KCNMA1 mRNA (Fig 5). 
Our failure to detect a reduction of BK channel α-subunit by Western blotting or 
immunocytochemistry may have several reasons. It appears that the three commercially 
available antibodies that we tested were of inferior quality for Western Blotting. Similarly, a 
specific immunocytochemical staining reaction was not achieved despite extensive testing on 
cell lines and formalin fixed tissue specimens. Further work is required to fine tune the 
experimental conditions of Western blotting for BK channel and to obtain or develop better 
antibodies. For example, others reported that BK channel extracted from glioma is adversely 
affected by boiling. 170. Thus, the boiling in presence of reducing agents that we applied 
before loading the SDS PAGE might have impaired quantification of BK channel protein 
knockdown. However, changing the preparation of the lysates before loading the gel did not 
alter the banding pattern nor the banding intensity (data not shown). 
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One might also argue that the inability to demonstrate a reduction of BK channel α-subunit on 
a protein level following siRNA is in favour of unspecific action of siRNA with no effect on 
BK channel. However, our collaborator Karl Kunzelmann (Department of Physiology, 
University of Regensburg) found strong indirect evidence that KCNMA1 expression is greatly 
enhanced in the cellular membrane of PC-3 as compared to BPH-1. In an electrophysiological 
approach, he could show that BK channel dependent K+ currents in PC-3 are significantly 
reduced in response to the siRNA K2, as compared control siRNA (unpublished data). 
Importantly, patch clamp experiments revealed that the density of active BK channels is much 
higher in PC-3 than in BPH-1. Furthermore, transfection of siRNA K2 in PC-3 significantly 
reduced both sensitivity to the BK channel blocker paxilline and the amount of BK channels 
in a randomly selected patch of the cell membrane. Taken together, these electrophysiological 
data strongly suggest that siRNA K2 reduces expression of the BK channel. The data also 
support the view that the failure to demonstrate protein expression of BK channel by Western 
Blot was most likely due to technical problems.  
 
3.8 BK channel meets estradiol in prostate cancer 
The known regulation of BK channel activity by 17β-estradiol is particularly intriguing 102. 
17β-estradiol and structurally related molecules, such as tamoxifen, interact with the 
extracellular domain regulatory subunit β1 of the BK channel and may activate the BK 
channel102,204,205. However, recent data suggest that the regulation of the BK channel by 
tamoxifen is much more complicated. Apparently, activity of BK channels is inhibited by 
tamoxifen, if the channels are composed of α-subunits only. In contrast β- tamoxifen may 
increase the activity of the BK channel when β subunits are present 206.  
The role of estrogens in regulation and organisation of the benign prostate may have been 
underestimated in the past 27. There is increasing evidence suggesting that estrogens cooperate 
with androgens to induce PCa194,207. In detail, prolonged treatment of adult rodents with 
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estrogens along with androgens leads to epithelial metaplasia, PIN-like lesions and even 
adenocarcinoma of prostate27. One major effect of androgen ablation therapy is increasing 
estrogen levels relative to androgens. Taking these observations together, it could be 
speculated that androgen independent growth of prostate cancer might be triggered by 
estrogens, i.e. that the tumour cell might become stimulated by estrogens under conditions of 
androgen withdrawal. This is supported by observations that in an artificial model of LNCaP 
progression towards androgen independency estrogen regulated genes were activated 208.  
 
In our experiments BK channel was shown to be constitutively active in PC-3, whereas BPH-
1 contained a pool of BK channels that could be activated by 17β-estradiol (Fig 4). Thus, we 
propose that increased activation of BK channel contributes to growth either by amplification 
and overexpression (PC-3) or by activation through 17β estradiol (BPH-1). Interestingly, 
expression of mRNA of estrogen receptors is detectable in PC-3 and BPH-1 209. However, in 
PC-3 the expression is reported to be as low as in breast carcinomas that are considered 
negative for estrogen receptor by immunohistochemistry 210. Our data linking BK channel to 
17β estradiol in prostate cancer support the notion that BK channel is an attractive putative 
target for treatment of androgen insensitive PCa.  
 
3.9. Putative mechanisms of K+ channels in cancer 
A growth promoting effect of BK channel is not unique to prostate cancer, but has also been 
demonstrated in astrocytoma 105 193. Similarly to our results in PC-3, ibtx decreased growth of 
the glioma cell line D54-MG 105. As amplification at 10q22 has not been reported in 
astrocytoma, other mechanisms may be responsible for KCNMA1 overexpression in this 
tumour type. Diverse types of K+ channels have been found to be overexpressed and 
activated in a number of tumour cell lines as compared to benign controls. These include 
Ca2+- activated K+ currents, Shaker-type voltage-gated K+ currents, the ether-a-go-go (EAG) 
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family of voltage gated K+ currents, inward rectifier K+ currents, ATP sensitive K+ current 
and swelling-activated K+ current 211. These previous reports support the notion that K+ 
gating is important to regulation of cell growth. The precise mechanism by which K+ 
channels promote tumour cell growth is still unknown.  
 
It has been known for a long time that tumour cells have different electrophysiological 
properties than normal cells 212. In particular, tumour cells have a lower resting membrane 
potential. Consequently, membrane depolarisation has been suggested an important 
precondition for unlimited tumour cell growth. A first model predicts that the low membrane 
potential facilitates Ca2+ influx into the cell due to activation of voltage dependent Ca2+ 
channels at lower membrane potentials 189. Intriguingly, several growth hormones such as 
epidermal growth factor (EGF), interleukin 2 (IL-2), and insulin induce sustained oscillations 
of membrane potential, which may be important to tumour cell proliferation 189.  
In addition, it has recently been reported that survival promoting translocation of transcription 
factor NFAT (nuclear factor of activated T cells) to the nucleus in response to NFkB (nuclear 
factor kappa-B) may depend on K+ channel activity213. 
 
Another putative mechanism by which K+ channels regulate cell growth may be related to 
changes in cell volume. It is known that activity of K+ channel can lead to a regulatory 
volume decrease (RVD) 189. Interestingly, decrease of cellular volume favours polymerisation 
of the actin cytoskeleton 214. Such polymerisation of actin cytoskeleton can have profound 
effects on critical proteins. For example, it favours translocation of CyclinD1 to the nucleus 
and allows sustained activation of integrin dependent signalling (MAP Kinases) 215.  
Taken together, BK channel may lead to activation of growth promoting pathways through 
RVD and consecutive polymerization of the actin cytoskeleton. However, the mechanisms of 
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how K+ channels affect tumor cell growth remain hypothetic, and further studies are needed 
to elucidate the downstream effects of K+ channels. 
In addition, K+ exit through K+ channels has been reported to favour in apoptosis, where cell 
shrinking precedes fragmentation of nuclear DNA 216. Thus, due to complex interaction with 
other signalling pathways, K+ channels may play a dual role in both cell proliferation and 
apoptosis. 
In another model, activity of K+ channels leads to activation of intra-cellular growth 
promoting factors. For example, it has previously been observed that epidermal growth factor 
activates K+ channels in myeloblastic leukaemia, which leads to activation of ERK2 MAP 
kinase. A mediator that links activity of K+ channels to activation of ERK2 has not been 
defined, yet 211. 
 
3. 10. Significance of this thesis 
The goal of this thesis was to identify a target of 10q22 amplification, and to validate its 
potential as a diagnostic and therapeutic target in prostate cancer. We propose that the 
potassium channel KCNMA1 has properties of an amplification target gene based on the 
following pieces of evidence: First, KCNMA1 is amplified in a fraction of late stage prostate 
cancer but not at early tumour stages. Second, there amplification is associated with 
overexpression in prostate cell lines. Third, inhibition of KCNMA1 by a specific blocker or 
siRNA technique reduces growth of the KCNMA1 amplified cell line PC-3. However, there is 
a missing piece to be added before a true oncogenic function of KCNMA1 can be considered. 
Unfortunately, we were not able to demonstrate altered expression of KCNMA1 on a protein 
level, most likely due to technical problems in the Western Blotting experiments. It will also 
be necessary to demonstrate such an association in clinical tumours. In addition, the growth 
inhibition in the PC-3 cell line by ibtx was statistically significant yet comparatively minor. In 
case of a drugable target, one would ideally demand a more pronounced effect. Optimization 
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of growth conditions in future experiments may allow demonstrating a greater effect of BK 
inhibition. The therapeutic potential of BK channel blockers has been recognized by 
pharmaceutical companies given the role of potassium channels in cardiovascular and 
neurological disorders, and in cancer. For example, the potassium channel TASK3 (KCNK9) 
at 8q24.3 has recently been found to be amplified in 10% and overexpressed in 44% of breast 
cancers 190. While ibtx is a toxin with no clinical utility, there are other BK channel blockers 
under development for clinical application (confidential information).  
 
3.11 Future directions 
The hypothesis that KCNMA1 is a putative amplification target gene at 10q22 should be 
strengthened by future experiments. Our study opens the following routes of future research: 
1. Knockdown of BK channel protein in response to siRNA should be demonstrated.  
2. The link of KCNMA1 amplification and increased expression in clinical specimens 
requires further study. For this purpose additional clinical specimens should be obtained and 
analysed. An antibody that allows semi-quantitative analysis of BK channel protein of 
formalin fixed tissue would be highly desirable. Ideally, it would allow direct correlation of 
KCNMA1 amplification and BK channel expression using a large scale TMA  
3. Amplification of 10q22 should be studied in more detail. FISH is an appropriate technique 
for this purpose, especially if applied to TMAs. High resolution screening for DNA sequence 
copy number changes across 10q22 could be achieved by high density BAC arrays or SNP 
arrays.  
4. This study focuses on KCNMA1 as amplification target gene. The role of other interesting 
genes at 10q22 including VDAC2, PSAP, RAI17 and PLAU should be analysed.  
5. The regulatory mechanisms by which ion channels are involved in functional regulation or 
execution of the cell cycle need to be elucidated. In the case of the BK channel, increased 
expression in late G1 phase might be related to the regulatory volume decrease that is 
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observed in G1 phase. However, is has also been shown that inhibition of BK channel in D54-
MG cells arrests the cells in S phase 105.  
 50
4. Materials& Methods 
4.1 Bacteria, Generation of Fish probes& Analysis of Gene Amplification 
Clinical specimens 
The 298 formalin-fixed and paraffin-embedded clinical specimens on the prostate tissue 
microarray were obtained from the archive of the Institute for Pathology, University Hospital 
Basel, Switzerland. The tissue microarray was constructed according to the method previously 
described 182. The diameter of each tissue spot was 0.6mm. Specimens were kept anonymous, 
and the experiments were performed according to the guidelines of the ethical committee of 
the University of Basel. 
 
10q22 tissue microarray (TMA) 
This is a TMA for screening 10q22 amplification. It contains 9 human samples derived from 
with advanced PCa that are characterised by an amplified signal using a probe for the gene 
vinculin (pers. Commun. W.Fu) and 6 controls. Each of these cases was represented in four 
replicates in order to covering a greater area and thereby allowing a better overview over the 
tumour. In addition there were two replicates of the cell lines PC-3, LNCaP, BPH-1, 
CWR22R, and JCA-1, each. The samples were recruited from archives of formalin fixed 
tissue of human biopsies and autopsies. 
 
Bacteria 
Bacteria strains were obtained from the Sanger Institute (Cambridge, UK). They belong to the 
RP-11 strains harbouring bacterial artificial chromosomes (BAC) from human genetic 
material with the exception of the BC RP13-39P13. The bacteria were plated for single colony 
and then the presence of the correct BAC was verified by PCR analysis of STS sequences 
present in the BAC. They were grown in low broth (LB) that contained 20 µg/ml 
chloramphenicol as selective marker. For solid media 1% agarose was added to the LB 
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medium. Bacteria were grown at 37°C except for BAC extraction. For extraction of DNA 
they were grown at room temperature to increase yield of BAC DNA. Bacs used in this study: 
RP11-464F9, RP11-296D9, RP11-312P12, RP11-399K21, RP11-162M1, RP11-325D15, 
RP11-428P16, RP13-39p12, RP11-6P10, RP11-202P11, RP11-342M3, RP11-506M13, 
RP11-182L21, RP11-137H2, RP11-459P11 All of these BAC provide resistance to the 
antibiotic chloramphenicol. 
LB is 10g Tryptone, 5g Yeast extract, 10g NaCl in 1l H20. Before use this growth medium 
was sterilised by autoclaving.  
 
Extraction of BAC DNA: 
The bacteria were grown for one day at room temperature. Then 2 ml bacteria culture were 
collected by centrifugation. The pellet was resuspended in GTE (50 mM Glucose, 25 mM 
TRIS, and 10mM EDTA in H2O) and lysed by addition of 1%SDS and 0.2N NaOH. The 
highly viscous solution was intensively mixed by pipetting in order to achieve complete lysis 
of the bacteria. Then protein was precipitated by addition of 7.5M Ammonium acetate 
(NH4Ac). After 5min incubation at room temperature insoluble material was precipitated by 
centrifugation at maximal speed. The DNA was precipitated from the supernatant by addition 
of isopropanol and centrifugation. The DNA pellet was resuspended in 2M NH3Ac, which 
allows removal of residual protein by centrifugation. The DNA was precipitated from the 
supernatant by addition of 1x volume isopropanol. Then it was resuspended in 50 µl H2O. 
Then 2µl RNAseA was added to degrade RNA in the DNA preparation.  
DNA concentration was measured in a Nanodrop Spectrophotometer measuring absorption at 
280nm 
Digoxigenin labelling 
1µg of purified plasmid DNA was labelled using a modified commercial nick translation kit 
(BioNick kit, Invitrogen). Instead of biotin (provided with the kit), digoxigenin was used as a 
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label to fit the needs of our established fluorescence detection system. In brief, the provided 
biotin nucleotide solution was replaced by a self-made nucleotide solution containing, 0.2 
mM each dCTP, dGTP, dTTP 0.1 mM dATP, 500 mM Tris-HCl (pH 7.8), 50 mM MgCl2, 
100 mM mercaptoethanol, and 100 µg/ml nuclease-free BSA. In a total reaction volume of 
48µl 5 µl Enzyme mix (BioNick kit) 5 µl Nucleotide solution, 1µl Digoxigenin (Roche), 1µl 
DNA Polymerase1 (Invitrogen), and 1 µg DNA were mixed. Nick translation was performed 
at 16°C for 90 min. Then the labelled KCNMA1 probe was precipitated by addition of 0.1x 
volume sodium acetate and 2x volume ethanol, and dissolved in 50 µl H20. 
 
Fluorescence in situ hybridisation (FISH) 
Paraffin removal (3x5min in Xylol followed by 2x2min Ethanol 95% and air-drying) and 
enzymatic tissue pre-treatment (Vysis pre-treatment solution, 80°C, 15 min) of tissue sections 
mounted on glass slides was performed in a VP2000 Processor device (Vysis). Slides were 
rinsed in water for 2 min, incubated in protease K solution (Vysis) at 37°C for 70min, and 
rinsed in water again. Subsequently, slides were dehydrated in an ascending ethanol series 
(70%, 80%, and 95%) and air-dried.  
A premixed hybridization cocktail containing 0.5 µl centromere 10 probe (CEP 10 Spectrum 
orange labelled; Vysis), 1.5 µl KCNMA1 probe (digoxigenin labelled), 1 µl Cot DNA 
(Invitrogen), and 7µl hybridization buffer (Vysis) was added to each slide. Slides were 
covered with cover slips and sealed with rubber cement (Starkey, La Grange, Illinois). For 
probe and target DNA denaturation, slides were heated to 72°C for 10 min. Probe and target 
DNA were allowed to hybridize overnight at 37°C.  
The next day, slides was washed to a stringency of 2xSSC, 0.3%NP40, pH= 7-7.5 at 72°C for 
2 min. The KCNMA1 probe was detected using the Dig detection kit (Roche) in a three-step 
immune reaction with a FITC coupled antibody as suggested by the manufacturer.  
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Specificity of the probe was tested on a human metaphase preparation. A probe was 
considered as specific when a co-localisation with a control probe that is specific to the 
centromere of chromosome 10 (CEP 10, Vysis) was observed. See Fig 2a for the BAC RP11-
428P16. All FISH probes used during this study were verified the same way (data not shown). 
In the case of amplicon screening (Fig 1B) 25 cells randomly selected cells were counted per 
tumour. For analysis of prevalence of 10q22 amplification the most prevalent amplification 
ratio was estimated in tumour cells. A case was considered amplified if the amplification ratio 
is >2. The amplification ratio is defined as number of probe signals versus number of 
centromere signals. 
 
4.2 Cell Culture and Analysis of BK channel modulation by Iberiotoxin and 17β-Estradiol 
Cell culture  
In routine cell culture all cell lines were grown in OPTI-MEM+ 10%FCS in vented flasks 
(75cm2, Falcon). The cells were split in a ratio of 1:5-1:10 when they were confluent. The 
cells were detached by incubation in a ready to use solution of 1:1000 Trypsin-EDTA 
(Amimed) for 5-15 min 
PC-3 
PC-3 was derived from a lumbar vertebral metastasis of a 62 year old white man in 1979217. It 
is highly progressed, for example it neither expresses AR nor PSA218and is highly 
tumourigenic forming tumours in nude mice at 100% frequency. Literature reports an 
approximate doubling time of 33 h218. I found a doubling time of <24h which might be due to 
high serum concentration or differences in medium formulation, but adaptation to in vitro cell 
culture due to high passage number is likely. It grows as single cells with no tendency to 
aggregate. It adheres readily to plastic surfaces of culture bottles and even to uncoated glass 
surfaces. It is easily detached by brief trypsinisation in 5-10 minutes. 
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LNCaP 
LNCaP cells were isolated from a needle aspiration biopsy of a lymph node metastasis from a 
50 year old white man219. These cells tend to adhere loosely to surfaces and may be easily 
detached220. LNCaP detaches as sheets or cell aggregates in culture at high cell density. The 
same phenomenon happens upon trypsinisation making counting difficult or unreliable. In 
order to circumvent this problem LNCaP was washed with Trypsin solution once before 
trypsinisation, which was 10-15 min. Then the remaining cell clumps were ripped by vigorous 
pipetting. If a highly reliable cell count was required, clumps of cells were removed by 
filtration through a cell strainer (Falcon). In our experimental condition, the doubling time 
was less than 24 h. Literature reports a doubling time of 2 days 218,220. This might be due to 
different media and high amount of FCS present. Another explanation is that the LNCaP 
strain used in this study has a relatively long history of culture and has already adapted to in 
vitro culture conditions. In an assay that achieved androgen independent growth of LNCaP, 
cells with high passage number showed increased number of genetic changes including 
microsatelite instability and allelic loss 221. These increased genetic alterations may be 
associated with the development of the androgen-unresponsive phenotype. Similar 
mechanisms may be involved in acceleration of growth that I observed in contrast to 
literature. As a consequence the cell line used in this study named LNCaP may have a 
significantly different genotype compared to the originally described cell lines. Thus 
repeating these experiments with other LNCaP strains with well-known passage number and 
genotype may yield different growth rates than reported here. 
BPH-1 
BPH-1 was derived from a 68 year old patient undergoing transurethral resection of the 
prostate (TURP) to help clear urinary obstruction consistent with BPH. The donor had not 
undergone any hormonal therapy and did not have malignant disease 222. The cells were 
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maintained in culture for 11 days and then immortalised with a virus carrying the SV40 T 
antigen and selected for resistance to geneticin.  
The cells grow as solid monolayer of a typical epithelial phenotype. This cell line does not 
form tumours in nude mice, although small clumps of cells were recovered from the graft 
sites indicating that cells survived in the host animals223. 
Growth experiments with Iberiotoxin and 17 β-Estradiol 
For the proliferation assays, 25’000 cells were plated per well of a 6-well plate (Falcon) in 
3ml OPTI-MEM+10% FCS. The medium was changed to 3ml OPTI-MEM+1% FCS after 1 
day of growth. At day 2 after seeding the medium was changed to OPTI-MEM+ 
0.4%Albumax (Invitrogen) containing the agent of interest. In addition the solvents, PBS or 
ethanol, respectively, were added to achieve comparable results. Iberiotoxin was diluted in 
PBS and used at a final concentration of 20 nM. 17 b-Estradiol (Sigma) was diluted in 70% 
ethanol and used at a final concentration of 1 nM 
After two days of growth the cells were detached and total cell number was counted in a 
Neubauer chamber. Then the virtual growth rate k form the equation A(t=2)=A(t=0)ekt was 
calculated. A(t=0) is cell number at day 0, when estradiol and iberiotoxin were added. A(t=2) is 
the cell number at day 2. t is time in days. 
 
4.3 PCR and Analysis of mRNA Expression 
PCR 
PCR Primers were designed using net-based primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) generating primer with a predicted annealing temperature of 
53-61°C using the TMUtility.1.5 software (http://www.idahotech.com/downloads_up/ 
index.html) for prediction of the annealing temperature using the LightCycler Fast Start DNA 
Master Sybr Green kit (Roche Molecular Diagnostics) with primer concentration of 50 µM 
and 2mM Mg2+. For gene expression analysis using LightCycler technology the PCR primers 
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were selected to generate 100-300 bp amplification products (See Table 2). Whenever 
possible these products were selected to span at least one exon/ intron boundary as predicted 
by ensembl (www.ensembl.org) to reduce the effect of contamination by genomic material 
due to incomplete DNA digestion during RNA extraction. For LightCycler analysis of gene 
expression the LightCycler Fast Start DNA Master Sybr Green kit (Roche molecular 
Diagnostics) was used following the suppliers suggestions. 
Routinely conventional PCR was performed using 0.4 µl Taq Polymerase (Qiagen), 2 µl 
dNTP (2.5 nM) each and 1 µl both forward and reverse Primer (10 µM). The template was 
added in a reasonable low concentration. Water was added to 20 µl. 
For colony PCR the template was added without performing DNA purification by directly 
streaking very little material of the clone of interest (e.g. a given E.coli strain) into the PCR 
tube. Then the prepared PCR master mix was added and the reaction immediately started. 
The routine PCR protocol was an initial step at 95°C for 3 min. Then the PCR cycles were: 
melting at 95°C 30 sec, annealing 52-59°C 30 sec, DNA synthesis at 72°C 1min. 25-40 PCR 
cycles. Then the product was cooled to 4°C.  
PCR Primers: 
See table ‘PCR primers, genes’ 
 
Gel electrophoresis 
Standard agarose gels contained 1% agarose in 1x TAE Buffer and 4 µl Ethidiumbromide per 
100ml gel. Running buffer was TAE. DNA or RNA samples were mixed with Blue Juice 
usually in a ratio of 4:1 for PCR and 1:1 for extracted DNA or RNA. Then 10 µl were loaded 
and the gel was run for 15min- 30min at a constant voltage of 60-120V, respectively. 1x TAE 
was prepared from a 50x TAE stock. 50x TAE stock is 242g TRISbase, 57.1 ml acetic acid, 
100ml 0.5M EDTA pH=8.0 in a total volume of 1l.  
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RNA extraction  
The material (cell lines or frozen genomic material) was lysed by addition of Trizol 
(Invitrogen). Lysis was improved by vigorous shaking. 0.2ml of chloroform was added per 
1ml of Trizol. After mixing by vigorous shaking the lysates was incubate at room temperature 
for 2-3 min. Then it was centrifuged at maximally 12’000g for 15 min at 4°C. The aqueous 
upper phase containing the RNA was transferred into a new tube. Then 0.5 ml of isopropanol 
was added per 1ml of Trizol initially used. The samples were incubated at room temperature 
for 15 min, which was followed by centrifugation at maximally 12’000g for 15 min at 4°C. 
Then RNA pellet was dissolved in the RLT buffer of the RNAeasy minikit. The supplied 
protocol of the RNA minikit was followed without modification including the optional DNA 
digestion. This protocol was followed because Trizol is more potent in lysis (especially in the 
case of tumour biopsy material) and the on column protocol of the RNAeasy minikit allows 
efficient removal of genomic DNA and avoids contamination with DNAse (pers. Comm. Dr. 
K. Struckmann). 
For analysis of siRNA efficiency, the unmodified RNAeasy kit including the optional DNA 
on column digestion step was used. In this case the provided RLT buffer of the RNAeasy 
minikit conveniently achieves lysis of the cells in the culture vial. Thus there is no need to 
perform the more complicated protocol described above. 
Extracted RNA was stored for short terms in the provided RNAse free water (RNAeasy mini 
kit) at -20°C.  
cDNA synthesis 
For cDNA synthesis the superscript II cDNA synthesis kit (Invitrogen) was used according to 
the manufacturer’s instructions. Preferentially 1 µg total RNA was transcribed. For 
LightCycler analysis of gene expression this cDNA solution was diluted 1:50 using 5 µl per 
reaction. 
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Oligo dT were used as primers for the cDNA synthesis excepted from the RNA extracted 
from human prostate cancer biopsy that was transcribed with random hexamers.  
 
4.4 siRNA and Western blotting 
siRNA 
siRNA design: In order to avoid problems with target sequence selection we chose a Qiagen 
offer to design and synthesise custom siRNA (k1:gactggcagagtcctggttgt, k2: 
gtgggtctgtccttccctact, k3: gaccgtcctgagtggccatgt, k4: acgcccttagaggtggctaca). In addition we 
ordered control (non-silencing) siRNA (Qiagen #1022076) and fluorescent-labelled control 
(non-silencing) siRNA, Rhodamine (Qiagen #1022083) as random sequence inactive siRNA 
controls. The lyophilised siRNA was solved in the provided siRNA buffer (100mM KOAc, 
30mM HEPES KOH, 2mM MgOAc, pH=7.4, 1min 90°C, 1h 37°C, and stored for daily use at 
–20°C) 
-Transfection: For transfection we chose Lipofectamine 2000 (Invitrogen, #11668-027) as 
best suited transfection agent for our cell line PC3 out of the selection Lipofectamine 2000, 
Oligofectamine (Invitrogen, #12252-011), siPORT™ Amine (Ambion, #4502), and siPORT™ 
Lipid (Ambion, #4504). For transfection we basically followed suppliers instructions taking 
care not to mix the transfection agents too intense, which could destroy the formed 
transfection complexes. 50’000 cells were seeded into one well of a 6-well BD Falcon™ Cell 
Culture Plate (Becton-Dickinson, #353046) one day before transfection in 3 ml OPTI-MEM 
(Gibco, 31985-047) containing 10% FCS (Amimed, 2-01F00-I). When transfecting cells no 
antibiotics were used to avoid toxic effects of these compounds in combination to the 
transfection agents (see product descriptions). For transfection 5 µl of siRNA stock solution 
(20nM) was added to 250 µl OPTI-MEM and vortexed. Then 5 µl Lipofectamine2000 was 
added to 250 µl OPTI-MEM and mixed by simply inverting the tube. After 5 min incubation 
the two solutions were combined, carefully mixed and incubated for 20 min. The cells were 
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washed once with Optimem. Then 2.5 ml OPTI-MEM was applied and the 0.5ml transfection 
complex solution was added onto the cells and carefully mixed by rocking the dish back and 
forth. After 4h of incubation the medium was changed to 3 ml OPTI-MEM with 10% FCS 
washing away the transfection medium.  
Western blotting: 
For western blotting, cells were grown in 6-well plates (Falcon). The cells were lysed by 
addition of 150-200 µl lysis buffer (list see below) and the lysat was transferred into 1.5ml 
Eppendorf tubes. Solid fragments were removed by centrifugation. The lysates were stored at 
-20°C. 
Protein concentration:  
Was measured using the Bio-Rad Protein Assay Dye Reagent Concentrate (BioRad) 
following the manufacturer’s instructions. 
Lysis buffers: 
2%SDS 
50mM TRIS CL (pH 6.8), 2% SDS, 10% Glycerol 
This buffer may be prepared and stored at room temperature. Add 100mM dithiotreitol (DTT) 
before use. This buffer may be used as loading buffer. In this case double the concentration of 
all components and add 0.2% bromophenol blue. 
1% Triton 
Triton-X100 10 mM Tris, pH 7.4 Extract Buffer:  
100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 
1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM PMSF, 0.5% Triton-
buffer 
CSK 
0.5% Triton-X100, 100mM NaCl, 300mM Sucrose, 10mM sodium phosphate, 10% Glycerol, 
p=6.8 
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add prior to use from fresh stock: 
2µg/ml Leupeptin, 1mM PMSF, 10mM NaF, 2.5 mM Na3VO4, 5 µl/ml protease inhibitor 
mix (Sigma) 
PMSF is unstable and must be added prior to use, even if added previously. 
This buffer also contains phosphatase inhibitors and may be used for preparation of 
phosphorylated protein. 
To the 2% SDS and Triton X100 Lysis buffers 1 tablet of complete mini protease inhibitor 
(Roche) per 10 ml of lysis buffer was added just before use. 
BK channel antibodies: APC 107 (Alomone labs); MaxiK-a, rabbit polyclonal (Affinity 
Bioreagents); Maxi Potassium channel alpha antibody (Abcam); anti-tubulin (bovine), mouse 
IgG1, monoclonal (Molecular Probes), Mouse monoclonal (6C5) to GPDH (Abcam) 
Horse radish peroxidase coupled goat anti rabbit (Jackson Immuno Research Laboratories); 
Horse radish peroxidase coupled goat anti mouse (Jackson Immuno Research Laboratories) 
Sodium dodecylsulfate polyacrylamid gel electrophoresis (SDS PAGE) 
Antibodies were validated in a self prepared 6% acrylamin/bisacrylamid gel 224. 5ml gel 
contained 2.6ml H2O, 1ml 30% Acrylamid Mix (supplier), 1.5ml Tris pH=8.8, 0.05 ml 10% 
SDS, 0.05 ml ammonium persulfate, 4 µl TEMED. On top of this resolving gel was a 5% 
stacking gel. 1 ml of this stacking gel contained: 0.68 ml H2O, 0.17 ml 30% Acrylamid Mix 
(supplier), 0.13 ml Tris pH=6.8, 0.01 ml 10% SDS, 0.01 ml ammonium persulfate, 1 µl 
TEMED.  
Loading, running of the gel, and transfer to PVDF membrane were performed as described by 
Sambrook et al. 224 
For analysis of BK channel protein knockdown in response to siRNA, precast NuPAGE 
Novex 4-12% Bis-Tris gels (Invitrogen) were used. The supplied protocol was followed for 
preparing of the samples, running of the gel, and transfer to a PVDF membrane. 
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The Colour Markers, High Range, (M.W. 29,000-205,000) was used as molecular weight 
marker (Sigma, C 3312) 
Hybridisation of antibodies: 
After transfer the PVDF membrane was blocked by incubation in phosphate buffered saline 
(PBS), 0.05% Tween, 4% dry milk for 15 min at RT. Then the blocking buffer was washed of 
with PBS and the 1° antibody was incubated. It was diluted in PBS, 0.05% Tween, 0.4% 
BSA. The membrane was washed 3 times in PBS, 0.05% Tween for at least 15 min. Then the 
secondary HRPT coupled antibody was incubated. It was diluted in PBS, 0.05% Tween, 4% 
dry milk. Then the membrane was washed 3 times in PBS, 0.05% Tween for at least 15 min.  
The antibody staining was detected using the ECL Plus™ Western Blotting Detection 
Reagents (Amersham Biosciences) was used. The membrane was exposed to a Kodak X-
Omat Film to detect cheminoluminescence. Exposure times were 2-3 min for the anti-tubulin 
1° antibody and >15 min for anti BK channel antibodies. The films were developed in a Curix 
table-top processor (AGFA).  
 
Table 2: ‘PCR primers’ 
Primer Pair Forward sequence Reverse sequence Length of product 
Calcineurin1 GACATCCATGGCCAATTTTT TTCATGGTTGCCTCTCAGAA  
Calcineurin2 CTGACTCCCACAGGGATGTT TGCGGTGTTCAGAGAATTGA  
Anx71 GCTGCCAACTTCGATGCTAT AGAGGGCCAGGATCAGTTCT  
Anx72 CTTGCCACAAGAAGCTTTCC TGTGCCAGCACCTTTCA  
Plau1 ACTCCAAAGGCAGCAATGAA GGCCTTTCCTCGGTAAAAGT  
Plau2 GTCACCACCAAAATGCTGTG GCGGATCCAGGGTAAGAAGT  
Kcnma11 ATATCCGCCCAGACACTGAC ATCGTTGGCTGCAATAAACC  
KCNMA12 TTGGACCAAGACGATGATGA CCTCTAAGGGCGTTTTCCTC  
DLG51 CTGTGGGAGACAGGATCGTT GGCTCGAAAACTCAGCATCT  
DLG52 CATCTGTCATCGACCCACTG GCAGGACTGTCATCCTCCAC  
MYST41 AAAGGGGCACCTCAGTATCC GGATGGGTGTCCACTACTGC  
MYST42 AAGCTCTTCCTGGACCACAA TGAGAAACCGTCCAAATCCT  
GPDH GAAATCCCATCACCATCTTCC CAGAGATGATGACCCTTTTGG  
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